629 The origin of potency and mutant-selective inhibition by bivalent ATP-allosteric EGFR inhibitors 2023
F Wittlinger, SP Chitnis, CD Pham, T Damghani, IK Schaeffner, MQ Deng, BC Ogboo, A Rasch, TS Beyett, B Buckley, F Feru, T Shaurova, C Knappe, MJ Eck, PA Hershberger, DA Scott, **SA Laufer**, DE Heppner
ChemRxiv; DOI: 10.26434/chemrxiv-2023-zzfc3

628 Inherent Fluorescence Demonstrates Immunotropic Properties for Novel Janus Kinase 3 Inhibitors 2023
J Laux, M Martorelli, S Strass, D Schollmeyer, F Maier, M Burnet, **SA Laufer**
ACS Pharmacology & Translational Science 2023, 6, 10, 1433-1452; doi.org/10.1021/acsptsci.3c00119

627 Linking ATP and allosteric sites to achieve superadditive binding with bivalent EGFR kinase inhibitors 2023
F Wittlinger, BC Ogboo, E Shevchenko, T Damghani, CD Pham, IK Schaeffner, BT Oligny, SP Chitnis, TS Beyett, A Rasch, B Buckley, DA Urul, T Shaurova, EW May, EM Schaefer, MJ Eck, PA Hershberger, A Poso, **SA Laufer**, DE Heppner
ChemRxiv; DOI: 10.26434/chemrxiv-2023-cs3xn-v2

626 Pitfalls and considerations in determining the potency and mutant selectivity of covalent epidermal growth factor receptor inhibitors 2023
KW Hoyt, DA Urul, BC Ogboo, F Wittlinger, **SA Laufer**, EM Schaefer, EW May, DE Heppner
ChemRxiv; DOI: 10.26434/chemrxiv-2023-tkqqk

625 Tricyclic protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death 2023
M Juchum, R Selig, **S Laufer**, W Albrecht
US Patent 11,731,968

624 Isolation and Identification of Phytocompounds from Maytenus dhofarensis and Their Biological Potentials 2023
F Al-Rubaiai, ZZ Al-Shariqi, KS Al-Shabibi, J Husband, AM Al-Hattali, M Goettert, **S Laufer**, Y Baqi, SI Hassan, MO Fatope
Molecules 28 (16), 6077

623 Imidazoquinolines with improved pharmacokinetic properties induce a high IFNα to TNFα ratio in vitro and in vivo 2023
M Keppler, S Straß, S Geiger, T Fischer, N Späth, T Weinstein, A Schwamborn, J Guezguez, JH Guse, **S Laufer**, M Burnet
Frontiers in Immunology 14, 1168252

622 Targeting SARS-CoV-2 Main Protease (MPro) with Kinase Inhibitors: A Promising Approach for Discovering Antiviral and Anti-inflammatory Molecules against SARS-CoV-2 2023

DB Anton, J Galvez Bulhões Pedreira, ML Zvirtes, **SA Laufer**, RG Ducati, M Goettert, LF Saraiva Macedo Timmers
Journal of Chemical Information and Modeling; doi.org/10.1021/acs.jcim.3c00324

621 Luteolin-7-O-Glucoside 对 6-OHDA 诱导的未分化和 RA 分化 SH-SY5Y 细胞损伤的神经保护作用 2023
LF Hoffmann, A Martins, F Majolo, V Contini, **S Laufer**, MI Goettert
中国神经再生研究 (**英文版**) 18 (6), 1265

620 A patent review of MAPK inhibitors (2018–present) 2023
VR Wydra, RB Ditzinger, NJ Seidler, FW Hacker, **SA Laufer**
Expert Opinion on Therapeutic Patents 33 (6), 421-444

619 Immune cell targeted fumaric esters support a role of GPR109A as a primary target of monomethyl fumarate in vivo 2023
S Straß, J Geiger, N Cloos, N Späth, S Geiger, A Schwamborn, L De Oliveira da Cunha, M Martorelli, JH Guse, T Lucas Sandri, M Burnet, **S Laufer**
Inflammopharmacology 31 (3), 1223-1239

618 Neural regeneration research model to be explored: SH-SY5Y human neuroblastoma cells 2023
LF Hoffmann, A Martins, F Majolo, V Contini, **S Laufer**, MI Goettert
Neural Regeneration Research 18 (6), 1265-1266

617 Design and Optimization of Novel Benzimidazole- and Imidazo[4,5-b]pyridine-Based ATM Kinase Inhibitors with Subnanomolar Activities 2023
T Dimitrov, AA Moschopoulou, L Seidel, T Kronenberger, M Kudolo, A Poso, C Geibel, P Wölffing, D Dauch, L Zender, D Schollmeyer, J Bajorath, M Forster, **S Laufer**
Journal of Medicinal Chemistry; doi.org/10.1021/acs.jmedchem.2c02104

616 Selective Inhibitors of Janus Kinase 3 Modify Responses to Lipopolysaccharides by Increasing the Interleukin-10-to-Tumor Necrosis Factor α Ratio 2023
J Laux, M Martorelli, N Späth, F Maier, M Burnet, **SA Laufer**
ACS Pharmacology & Translational Science; doi.org/10.1021/acsptsci.3c00043

615 The European Federation for Medicinal Chemistry and Chemical Biology (EFMC) Best Practice Initiative: Hit Generation 2023
J Quancard, A Vulpetti, A Bach, B Cox, SM Guéret, IV Hartung, HF Koolman, **S Laufer**, J Messinger, G Sbardella, R Craft
ChemMedChem 18 (9), e202300002

614 MKK4 Inhibitors—Recent Development Status and Therapeutic Potential 2023
L Katzengruber, P Sander, **S Laufer**
International Journal of Molecular Sciences 24 (8), 7495

613 COVID-19 therapeutics: small-molecule drug development targeting SARS-CoV-2 main protease 2023
T Kronenberger, **SA Laufer**, T Pillaiyar
Drug Discovery Today, 103579

612 Isostearic acid is an active component of imiquimod formulations used to induce psoriaform disease models 2023
S Straß, J Geiger, M Martorelli, S Geiger, N Cloos, M Keppler, T Fischer, L Riexinger, A Schwamborn, J Guezguez, N Späth, S Cruces, JH Guse, T Lucas Sandri, M Burnet, **S Laufer**
Inflammopharmacology 31 (2), 799-812

611 3-benzoyl-1h-pyrrolo [2, 3-b] pyridine derivatives as mkk4 inhibitors for treating liver diseases 2023
R Selig, S Laufer, W Albrecht
US Patent App. 17/792,685

610 Structural elements that enable specificity for mutant EGFR kinase domains with next-generation small-molecule inhibitors. 2023
T Damghani, F Wittlinger, TS Beyett, MJ Eck, **SA Laufer**, DE Heppner

609 Examining molecular factors of inactive versus active bivalent EGFR inhibitors: A missing link in fragment-based drug design. 2023
F Wittlinger, BC Ogboo, CD Pham, IK Schaeffner, SP Chitnis, T Damghani, TS Beyett, A Rasch, B Buckley, DA Urul, T Shaurova, EW May, EM Schaefer, MJ Eck, PA Hershberger, **SA Laufer**, DE Heppner

608 Discovery of Polyphenolic Natural Products as SARS-CoV-2 M^{pro} Inhibitors for COVID-19 2023
N Krüger, T Kronenberger, H Xie, C Rocha, S Pöhlmann, H Su, Y Xu, **SA Laufer**, T Pillaiyar
Pharmaceuticals 16 (2), 190

607 Centrally active p38alpha inhibiting compounds 2023
S Laufer, W Albrecht, P Koch, N Walter
US Patent App. 17/638,751

606 Ready-to-use nanopore platform for ethanolamine quantification using an aptamer-based strand displacement assay. 2023
I Quint, J Simantzik, L Kaiser, **S Laufer**, R Csuk, D Smith, M Kohl, HP Deigner
bioRxiv, 2023.02. 27.530168

605 Pharmacy Archives 2023
A Link, **S Laufer**, W Diederich, C Veale, A Artese, K Augustyns, ...
ARCHIV DER PHARMAZIE 356 (1)

604 Anticancer Drug Conjugates Incorporating Estrogen Receptor Ligands 2023
DP Zlotos, T Kronenberger, **SA Laufer**
Pharmaceutics 15 (1), 67

603 Antiulcerogenic Potential of the Ethanolic Extract of *Ceiba speciosa* (A. St.-Hil.) Ravenna Evaluated by In Vitro and In Vivo Studies 2022
JA Dörr, F Majolo, L Bortoluzzi, EZ de Vargas, J Silva, M Pasini, SN Stoll, R Lopes da Rosa, M Moreira Figueira, M Fronza, WO Beys-da-Silva, A Martins, H Gaspar, RP Pedrosa, **S Laufer**, MI Goettert
International Journal of Molecular Sciences 23 (24), 15634

602 Direct 3D printed biocompatible microfluidics: assessment of human mesenchymal stem cell differentiation and cytotoxic drug screening in a dynamic culture system 2022
O Riester, **S Laufer,** HP Deigner
Journal of Nanobiotechnology 20 (1), 1-18

601 Synthesis of a biocompatible benzophenone-substituted chitosan hydrogel as novel coating for PEEK with extraordinary strong antibacterial and anti-biofilm properties 2022
M Borgolte, O Riester, I Quint, F Blendinger, V Bucher, **S Laufer**, R Csuk, L Scotti, H-P Deigner
Materials Today Chemistry 26, 101176

600 Structural Basis for Inhibition of Mutant EGFR with Lazertinib (YH25448) 2022
DE Heppner, F Wittlinger, TS Beyett, T Shaurova, DA Urul, B Buckley, CD Pham, IK Schaeffner, B Yang, BC Ogboo, EW May, EM Schaefer, MJ Eck, **SA Laufer**, PA Hershberger
ACS Medicinal Chemistry Letters 13 (12), 1856-1863

599 Novel Approach to Pharmaceutical 3D-Printing Omitting the Need for Filament—Investigation of Materials, Process, and Product Characteristics
T Pflieger, R Venkatesh, M Dachtler, K Eggenreich, **S Laufer**, D Lunter 2022
Pharmaceutics 14 (11), 2488

598 Heteroaryl-substituted pyrazolo-pyridine protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death 2022
B Pfaffenrot, R Selig, **S Laufer**, W Albrecht
US Patent App. 17/630,105

597 Synergy of R-(–) carvone and cyclohexenone-based carbasugar precursors with antibiotics to enhance antibiotic potency and inhibit biofilm formation 2022
O Riester, P Burkhardtsmaier, Y Gurung, **S Laufer**, HP Deigner, MS Schmidt
Scientific Reports 12 (1), 18019

596 Influence of diet and MOG35-55 peptide preparation on severity, survival, incidence and body weight in murine experimental autoimmune encephalomyelitis 2022
M Martorelli, J Laux, M Dengler, T Fischer, D Canjuga, A Vaiceliunaite, F Maier, M Burnet, **S Laufer**
MULTIPLE SCLEROSIS JOURNAL 28 (3_ SUPPL), 221-221

595 Discovery and Development of First-in-Class ACKR3/CXCR7 Superagonists for Platelet Degranulation Modulation 2022
A Bayrak, F Mohr, K Kolb, M Szpakowska, E Shevchenko, V Dicenta, A-K Rohlfing, M Kudolo, T Pantsar, M Günther, AA Kaczor, A Poso, A Chevigné, T Pillaiyar, M Gawaz, **SA Laufer**
Journal of Medicinal Chemistry 65 (19), 13365-13384

594 Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death 2022
W Albrecht, S Laufer, R Selig, P Klövekorn, B Präfke
US Patent App. 17/260,519

593 Pivotal blinded randomized trial of a novel pro-regenerative drug in post-resection liver failure 2022
A Abu Rmilah, K Li, E Larson, S Ellias, S Klotz, B Pfaffenroth, P Kloevekorn, R Selig, W Zhou, E Nelson, A Poso, H Chen, B Amiot, A Minshew, G Michalak, W Cui, W Albrecht, B Jung, O Trompak, S Zwirner, M Lutz, T Wuestefeld, **S Laufer**, L Zender, S Nyberg
Transplantation 106 (8 S), 19-20

592 Scaffold modified Vemurafenib analogues as highly selective mitogen activated protein kinase kinase 4 (MKK4) inhibitors 2022
M Juchum, B Pfaffenrot, P Klövekorn, R Selig, W Albrecht, L Zender, **SA Laufer**
European Journal of Medicinal Chemistry 240, 114584

591 Pharmacokinetic Optimization of Small Molecule Janus Kinase 3 Inhibitors to Target Immune Cells 2022
J Laux, M Forster, L Riexinger, A Schwamborn, J Guezguez, C Pokoj, M Kudolo, LM Berger, S Knapp, D Schollmeyer, J Guse, M Burnet, **SA Laufer**
ACS Pharmacology & Translational Science

590 Novel avenue towards liver regeneration and treatment of acute and chronic liver diseases: safety and PK profile from a first-in human (FIH) clinical trial for HRX-0215 as first in class MKK4 inhibitor 2022
B Jung, M Weissbach, M Lutz, R Selig, **S Laufer**, L Zender, M Feigh, M Berse, J Penski, E Kosmella, W Albrecht
Journal of Hepatology 77, S737-S738

589 Small-Molecule Thioesters as SARS-CoV-2 Main Protease Inhibitors: Enzyme Inhibition, Structure–Activity Relationships, Antiviral Activity, and X-ray Structure Determination 2022
T Pillaiyar, P Flury, N Krüger, H Su, L Schäkel, E Barbosa Da Silva, O Eppler, T Kronenberger, T Nie, S Luedtke, C Rocha, K Sylvester, MRI Petry,
JH McKerrow, A Poso, S Pöhlmann, M Gütschow, AJ O'Donoghue, Y Xu,
CE Müller, **SA Laufer**
Journal of Medicinal Chemistry 65 (13), 9376-9395

588 Super-conserved receptors expressed in the brain: biology and medicinal chemistry efforts 2022
A Bayrak, J Hanson, **S Laufer**, T Pillaiyar
Future Medicinal Chemistry 14 (12), 899-913

587 Publication Criteria and Requirements for Studies on Protein Kinase Inhibitors─ What Is Expected? ("It is pretty easy to make a bad kinase inhibitor") 2022
S Laufer, J Bajorath, M Gehringer, N Gray, S Frye, CW Lindsley
Journal of Medicinal Chemistry 65 (10), 6973 - 6974

586 Development of novel urea-based ATM kinase inhibitors with subnanomolar cellular potency and high kinome selectivity 2022
T Dimitrov, C Anli, AA Moschopoulou, T Kronenberger, M Kudolo, C Geibel, MP Schwalm, L Zender, M Forster, **S Laufer**
European Journal of Medicinal Chemistry 235, 114234

585 2, 2, 2-Trifluoroethanol-mediated hydroarylation of fluorinated alkynes with indoles: Application to diindolylmethanes 2022
P Flury, O Eppler, D Schollmeyer, **S Laufer**, T Pillaiyar
Archiv der Pharmazie, e2100488

584 Target Hopping from Protein Kinases to PXR: Identification of Small-Molecule Protein Kinase Inhibitors as Selective Modulators of Pregnane X Receptor from TüKIC Library 2022
EK Mustonen, T Pantsar, A Rashidian, J Reiner, M Schwab, **S Laufer**, O Burk
Cells 11 (8), 1299

583 ACKR3 regulates platelet activation and ischemia-reperfusion tissue injury 2022
AK Rohlfing, K Kolb, M Sigle, M Ziegler, A Bild, P Münzer, J Sudmann, V Dicenta, T Harm, MC Manke, S Geue, M Kremser, M Chatterjee, C Liang, H von Eysmondt, T Dandekar, D Heinzmann, M Günter, S von Ungern-Sternberg, M Büttcher, T Castor, S Mencl, F Langhauser,K Sies, D Ashour, MC Beker, M Lämmerhofer, SE Autenrieth, TE Schäffer, **S Laufer**, P Szklanna, P Maguire, M Heikenwalder, KAL Müller, DM Hermann, E Kilic, R Stumm, G Ramos, C Kleinschnitz, O Borste, HF Langer, D Rath, M Gawaz
Nature Communications 13 (1), 1-20

582 In vitro and in vivo anti-inflammatory and anticoagulant activities of Myrciaria plinioides D. Legrand ethanol leaf extract 2022
DJ Marmitt, S Bitencourt, CO Coura, M Berger, D Faleiro, DM Kich, B Caye, SM Immich, A Fernandes Frota, WO Beys-da-Silva, J Almeida Guimaraes, NM Barros Benevides, **S Laufer**, MI Goettert
Inflammopharmacology 30 (2), 565-577

581 Gefitinib-Tamoxifen Hybrid Ligands as Potent Agents against Triple-Negative Breast Cancer 2022

CM Abdelmalek, Z Hu, T Kronenberger, J Küblbeck, FJM Kinnen, SS Hesse, A Malik, M Kudolo, R Niess, M Gehringer, L Zender, PA Witt-Enderby, DP Zlotos, **SA Laufer**
Journal of Medicinal Chemistry 65 (6), 4616-4632

580 Neuroprotective Effect of Luteolin-7-O-Glucoside against 6-OHDA-Induced Damage in Undifferentiated and RA-Differentiated SH-SY5Y Cells 2022
SCH Rehfeldt, J Silva, C Alves, S Pinteus, R Pedrosa, **S Laufer**, MI Goettert
International Journal of Molecular Sciences 23 (6), 2914

579 Development of the first covalent monopolar spindle kinase 1 (MPS1/TTK) Inhibitor 2022
RA M. Serafim, A da Silva Santiago, MP Schwalm, Z Hu, CV Dos Reis, JE Takarada, P Mezzomo, KB Massirer, M Kudolo, S Gerstenecker, A Chaikuad, L Zender, S Knapp, **S Laufer**, RM Counago, M Gehringer
Journal of Medicinal Chemistry 65 (4), 3173-3192

578 Decisive role of water and protein dynamics in residence time of p38α MAP kinase inhibitors 2022
T Pantsar, PD Kaiser, M Kudolo, M Forster, U Rothbauer, **SA Laufer**
Nature Communications 13 (1), 1-14

577 The functional role of p38 MAPK pathway in malignant brain tumors 2022
N Grave, TB Scheffel, FF Cruz, L Rockenbach, MI Goettert, S Laufer, ...
Frontiers in Pharmacology 13

576 Discrepancy in interactions and conformational dynamics of pregnane X receptor (PXR) bound to an agonist and a novel competitive antagonist 2022
A Rashidian, EK Mustonen, T Kronenberger, M Schwab, O Burk, **SA Laufer**, T Pantsar
Computational and Structural Biotechnology Journal 20, 3004-3018

575 New Horizons in Drug Discovery-Understanding and Advancing Different Types of Kinase Inhibitors: Seven Years in Kinase Inhibitor Research with Impressive Achievements and New Future Prospects 2021
S Laufer, J Bajorath
Journal of Medicinal Chemistry 65 (2), 891-892

574 High-Throughput Screening Platform in Postnatal Heart Cells and Chemical Probe Toolbox to Assess Cardiomyocyte Proliferation 2021
C Carrillo García, C Becker, M Forster, S Lohmann, P Freitag, **S Laufer**, S Sievers, BK Fleischmann, M Hesse, D Schade
Journal of Medicinal Chemistry 65 (2), 1505-1524

573 Design of a “two-in-one” mutant-selective epidermal growth factor receptor inhibitor that spans the orthosteric and allosteric sites 2021
F Wittlinger, DE Heppner, C To, M Günther, BH Shin, JK Rana, AM Schmoker, TS Beyett, LM Berger, BT Berger, N Bauer, JD Vasta, CR Corona, MB Robers, S Knapp, PA Janne, MJ Eck, **SA Laufer**

Journal of Medicinal Chemistry 65 (2), 1370-1383

572 Biosynthesis of iron oxide magnetic nanoparticles using clinically isolated Pseudomonas aeruginosa 2021
AA Khan, S Khan, S Khan, S Rentschler, **S Laufer**, HP Deigner
Scientific Reports 11 (1), 1-10

571 Dataset (X) related to publication: Decisive Role of Water and Protein Dynamics in Residence Time of p38a MAP Kinase Inhibitors 2021
T Pantsar, **S Laufer**

570 Discovery of a Potent and Highly Isoform-Selective Inhibitor of the Neglected Ribosomal Protein S6 Kinase Beta 2 (S6K2) 2021
S Gerstenecker, L Haarer, M Schröder, M Kudolo, MP Schwalm, V Wydra, RAM Serafim, A Chaikuad, S Knapp, **S Laufer**, M Gehringer
Cancers 13 (20), 5133

569 Methacryloyl-GlcNAc Derivatives Copolymerized with Dimethacrylamide as a Novel Antibacterial and Biocompatible Coating 2021
M Borgolte, O Riester, T Kacerova, S Rentschler, MS Schmidt, S Jacksch, M Egert, **S Laufer**, R Csuk, HP Deigner
Pharmaceutics 13 (10), 1647

568 The pre-clinical discovery and development of osimertinib used to treat non-small cell lung cancer 2021
F Wittlinger, **SA Laufer**
Expert Opinion on Drug Discovery 16 (10), 1091-1103

567 1st IN CLASS SMALL MOLECULE INHIBITORS OF MKK4 EXERT PRONOUNCED THERAPEUTIC EFFICACY IN RODENT AND NON-RODENT MODELS OF ACUTE AND CHRONIC LIVER FAILURE 2021
S Klotz, A Abu Rmilah, B Pfaffenrot, P Kloevekorn, R Selig, K Li, W Zhou, E Nelson, A Poso, H Chen, B Amiot, Y Jia, A Minshew, G Michalak, W Cui, W Albrecht, J Birgit, O Trompak, S Zwirner, M Lutz, T Wuestefeld, **S Laufer**, SL Nyberg, L Zender
HEPATOLOGY 74, 157A-157A

566 Neuropsychiatric Disorders and COVID-19: What We Know So Far 2021
F Majolo, GL Silva, L Vieira, C Anli, LFSM Timmers, **S Laufer**, MI Goettert
Pharmaceuticals 14 (9), 933

565 Development of a Selective Dual Discoidin Domain Receptor (DDR)/p38 Kinase Chemical Probe 2021
S Röhm, BT Berger, M Schröder, D Chatterjee, S Mathea, AC Joerger, DM Pinkas, JC Bufton, A Tjaden, L Kovooru, M Kudolo, C Pohl, AN Bullock, S Müller, **S Laufer**, S Knapp
Journal of Medicinal Chemistry 64 (18), 13451-13474

564 Controlling the covalent reactivity of a kinase inhibitor with light 2021

M Reynders, A Chaikuad, BT Berger, K Bauer, P Koch, **S Laufer**, S Knapp, .D Trauner
Angewandte Chemie International Edition 60 (37), 20178-20183

563 Chemical Probes for Understudied Kinases: Challenges and Opportunities 2021
RAM Serafim, JM Elkins, WJ Zuercher, **SA Laufer**, M Gehringer
Journal of Medicinal Chemistry 65 (2), 1132-1170

562 Tricyclic protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death 2021
M Juchum, R Selig, S Laufer, W Albrecht
US Patent App. 17/254,071

561 Improved Multigram Route to a Tricyclic Key Intermediate for Dibenzosuberone-Based p38 Inhibitors via an Optimized Early-Stage Heck Coupling 2021
M Forster, HK Wentsch-Teltschik, **SA Laufer**
Organic Process Research & Development 25 (8), 1831-1840

560 Synthesis, Characterization, and in vivo Distribution of Intracellular Delivered Macrolide Short-Chain Fatty Acid Derivatives 2021
S Straß, A Schwamborn, M Keppler, N Cloos, J Guezguez, JH Guse, M Burnet, **S Laufer**
ChemMedChem 16 (14), 2254-2269

559 Design, Synthesis and Biological Evaluation of Novel Pyrazolo [1, 2, 4] triazolopyrimidine Derivatives as Potential Anticancer Agents 2021
S Aliwaini, B Abu Thaher, I Al-Masri, N Shurrab, S El-Kurdi, D Schollmeyer, B Qeshta, M Ghunaim, R Csuk, S Laufer, L Kaiser, HP Deigner
Molecules 26 (13), 4065

558 Addressing a Trapped High-Energy Water: Design and Synthesis of Highly Potent Pyrimidoindole-Based Glycogen Synthase Kinase-3β Inhibitors 2021
S Andreev, T Pantsar, R Tesch, N Kahlke, A El-Gokha, F Ansideri, L Grätz, J Romaco, G Sita, C Geibel, M Lämmerhofer, A Tarozzi, S Knapp, **SA Laufer**, P Koch
Journal of Medicinal Chemistry 65 (2), 1283-1301

557 Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death 2021
W Albrecht, **S Laufer**, R Selig, P Klövekorn, B Präfke
US Patent 11,040,027

556 Simplifying Submission Requirements for the *Journal of Medicinal Chemistry* 2021
CW Lindsley, J Barrow, K Chibale, ML Bolognesi, S Conway, W Denny, K Ding, **S Laufer**, L Lai, H Liu, N Neamati, T Suzuki, N Meanwell, W Young
Journal of Medicinal Chemistry 64 (12), 7877-7878

555 SARS-CoV-2 mutations in Brazil: from genomics to putative clinical conditions 2021
LFSM Timmers, JV Peixoto, RG Ducati, JFR Bachega, L de Mattos Pereira, RA Caceres, F Majolo, G Liberato da Silva, D Bublitz Anton, OA Dallagostin, JA Pegas Henriques, LL Xavier, MI Goettert, **S Laufer**
Scientific Reports 11 (1), 1-14

554 The European Federation for Medicinal Chemistry and Chemical Biology (EFMC) Best Practice Initiative: Phenotypic Drug Discovery 2021
J Quancard, A Bach, B Cox, R Craft, D Finsinger, SM Guéret, IV Hartung, **S Laufer**, J Messinger, G Sbardella, HF Koolman
ChemMedChem 16 (11), 1737-1740

553 Design and synthesis of 1H-pyrazolo [3, 4-b] pyridines targeting mitogen-activated protein kinase kinase 4 (MKK4)-A promising target for liver regeneration 2021
B Pfaffenrot, P Klövekorn, M Juchum, R Selig, W Albrecht, L Zender, **SA Laufer**
European Journal of Medicinal Chemistry 218, 113371

552 Kinases as potential therapeutic targets for anti-coronaviral therapy 2021
T Pillaiyar, **S Laufer**
Journal of Medicinal Chemistry 65 (2), 955-982

551 Current jakinibs for the treatment of rheumatoid arthritis: a systematic review 2021
CM Rocha, AM Alves, BF Bettanin, F Majolo, M Gehringer, **S Laufer**, MI Goettert
Inflammopharmacology 29 (3), 595-615

550 Design and Synthesis of Highly Selective Brain Penetrant p38α Mitogen-Activated Protein Kinase Inhibitors 2021
NM Tormählen, M Martorelli, A Kuhn, F Maier, J Guezguez, M Burnet, W Albrecht, **SA Laufer**, P Koch
Journal of Medicinal Chemistry 65 (2), 1225-1242

549 Combining aptamers and antibodies: Lateral flow quantification for thrombin and interleukin-6 with smartphone readout 2021
M Mahmoud, C Ruppert, S Rentschler, **S Laufer**, HP Deigner
Sensors and Actuators B: Chemical 333, 129246

548 A highly selective in vitro jnk3 inhibitor, fmu200, restores mitochondrial membrane potential and reduces oxidative stress and apoptosis in sh-sy5y cells 2021
SCH Rehfeldt, **S Laufer**, MI Goettert
International Journal of Molecular Sciences 22 (7), 3701

547 A special view of what was almost forgotten: p38δ MAPK 2021
DB Anton, RG Ducati, LFSM Timmers, S Laufer, MI Goettert
Cancers 13 (9), 2077

546 Synthesis, characterization and in vivo distribution of intracellular delivered macrolide SCFA derivatives. 2021
M Burnet, S Strass, A Schwamborn, M Keppler, J Guezguez, JH Guse, **S Laufer**, N Cloos
ChemMedChem 16 (14), 2254-2269

545 Proteinkinase Inhibitors 2021
S Laufer (Editor)
Topics in Medicinal Chemistry, Springer
ISBN 978-3-030-68179-1

544 Protein kinase mkk4 inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death 2021
B Praefke, P Klövekorn, R Selig, W Albrecht, **S Laufer**
US Patent App. 16/965,912

543 Identification of novel pregnane X receptor antagonists in the Tubingen kinase inhibitor collection (TuKIC) compound library 2021
EK Mustonen, T Pantsar, A Rashidian, **S Laufer**, M Schwab, O Burk
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY
394 (SUPPL 1), S43-S43

542 SARS-CoV-2 mutations in Brazil: from genomics to clinical conditions 2021
L Timmers, J Peixoto, R Ducati, JF Bachega, LM Pereira, RA Caceres, F Majolo, G Liberato Da Silva, D Bublitz Anton, MI Goettert, OA Dellagostin, J Henriques, L Xavier, **S Laufer**
Scientific Reports 11

541 Review of trials currently testing stem cells for treatment of respiratory diseases: Facts known to date and possible applications to COVID-19 2021
F Majolo, GL da Silva, L Vieira, LFSM Timmers, **S Laufer**, MI Goettert
Stem Cell Reviews and Reports 17 (1), 44-55

540 LXRα activation and Raf inhibition trigger lethal lipotoxicity in liver cancer 2021
R Rudalska, J Harbig, MT Snaebjornsson, S Klotz, S Zwirner, L Taranets, F Heinzmann, T Kronenberger, M Forster, W Cui, L D'Artista, E Einig, M Hinterleitner, W Schmitz, A Dylawerska, TW Kang, A Poso, MT Rosenfeldt, NP Malek, M Bitzer, **S Laufer**, BJ Pichler, N Popov, A Schulze, L Zender, D Dauch
Nature Cancer 2 (2), 201-217

539 *N*-(6-Chloro-3-nitropyridin-2-yl)-5-(1-methyl-1*H*-pyrazol-4-yl)isoquinolin-3-amine 2021
V Wydra, S Gerstenecker, D Schollmeyer, S Andreev, T Dimitrov, RAM Serafim, **S Laufer**, M Gehringer
Molbank 2021 (1), M1181

538 From off-to on-target: New BRAF-inhibitor-template-derived compounds selectively targeting mitogen activated protein kinase kinase 4 (MKK4) 2021

P Kloevekorn, B Pfaffenrot, M Juchum, R Selig, W Albrecht, L Zender, **SA Laufer**
European Journal of Medicinal Chemistry 210, 112963

537 Design and synthesis of novel fluorescently labeled analogs of vemurafenib targeting MKK4 2021
T Kircher, T Pantsar, A Oder, JP von Kries, M Juchum, B Pfaffenrot, P Kloevekorn, W Albrecht, R Selig, **S Laufer**
European Journal of Medicinal Chemistry 209, 112901

536 Molecular Design of a "Two-in-One" Orthosteric-Allosteric Chimeric Mutant Selective EGFR Inhibitor 2021
F Wittlinger, DE Heppner, C To, M Guenther, BH Shin, JK Rana, AM Schmoker, TS Beyett, PA Jänne, MJ Eck, **S Laufer**
Journal of Medicinal Chemistry 65 (2), 1370-1383

535 c-Jun N-terminal kinase inhibitors as potential leads for new therapeutics for Alzheimer's diseases 2020
SC Hepp Rehfeldt, F Majolo, MI Goettert, **S Laufer**
International Journal of Molecular Sciences 21 (24), 9677

534 The European Federation for Medicinal Chemistry (EFMC) Best Practice Initiative: Validating Chemical Probes 2020
J Quancard, B Cox, D Finsinger, SM Guéret, IV Hartung, HF Koolman, J Messinger, G Sbardella, **S Laufer**
ChemMedChem 15 (24), 2388-2390

533 Selective targeting of the αC and DFG-out pocket in p38 MAPK 2020
S Roehm, M Schröder, JE Dwyer, CS Widdowson, A Chaikuad, BT Berger, AC Joerger, A Krämer, J Harbig, D Dauch, M Kudolo, **S Laufer**, MC Bagley, S Knapp
European Journal of Medicinal Chemistry 208, 112721

532 Discovery of a novel class of covalent dual inhibitors targeting the protein kinases BMX and BTK 2020
M Forster, XJ Liang, M Schröder, S Gerstenecker, A Chaikuad, S Knapp, **S Laufer**, M Gehringer
International Journal of Molecular Sciences 21 (23), 9269

531 Duplex Shiny app quantification of the sepsis biomarkers C-reactive protein and interleukin-6 in a fast quantum dot labeled lateral flow assay 2020
C Ruppert, L Kaiser, LJ Jacob, **S Laufer**, M Kohl, HP Deigner
Journal of Nanobiotechnology 18 (1), 1-11

530 Chemical Space Exploration of Oxetanes 2020
FRS Alves, RM Couñago, **S Laufer**
International Journal of Molecular Sciences 21 (21), 8199

529 Discovery and Evaluation of Enantiopure 9*H*-pyrimido[4,5-*b*]indoles as Nanomolar GSK-3β Inhibitors with Improved Metabolic Stability 2020

S Andreev, T Pantsar, A El-Gokha, F Ansideri, M Kudolo, DB Anton, G Sita, J Romasco, C Geibel, M Lämmerhofer, MI Goettert, A Tarozzi**, SA Laufer,** P Koch
International Journal of Molecular Sciences 21 (21), 7823

528 Identifying representative kinases for inhibitor evaluation via systematic analysis of compound-based target relationships 2020
O Laufkötter, **S Laufer**, J Bajorath
European Journal of Medicinal Chemistry 204, 112641

527 Kinase inhibitor data set for systematic analysis of representative kinases across the human kinome 2020
O Laufkötter, **S Laufer**, J Bajorath
Data in Brief 32, 106189

526 New Horizons in Drug Discovery-Understanding and Advancing Kinase Inhibitors: Special Issue and Call for Papers 2020
S Laufer, K Briner, J Bajorath, GI Georg, S Wang
Journal of Medicinal Chemistry 63 (15), 7921-7922

525 Candidate drugs against SARS-CoV-2 and COVID-19 2020
DL McKee, A Sternberg, U Stange, **S Laufer**, C Naujokat
Pharmacological Research 157, 104859

524 An updated patent review of p38 MAP kinase inhibitors (2014-2019) 2020
V Haller, P Nahidino, M Forster, **SA Laufer**
Expert Opinion on Therapeutic Patents 30 (6), 453-466

523 Neuroprotective potential of Myrciaria plinioides D. Legrand extract in an in vitro human neuroblastoma model 2020
DJ Marmitt, C Alves, J Silva, S Pinteus, T Schneider, RCV Santos, EM de Freitas, R Pedrosa, **S Laufer**, MI Goettert
Inflammopharmacology 28 (3), 737-748

522 Dapsone is not a pharmacodynamic lead compound for its aryl derivatives 2020
T Scior, HH Abdallah, K Salvador-Atonal, **S Laufer**
Current Computer-aided Drug Design 16 (3), 327-339

521 Bioisosteric Replacement of Arylamide-Linked Spine Residues with *N*-Acylhydrazones and Selenophenes as a Design Strategy to Novel Dibenzosuberone Derivatives as Type I ½ p38α MAP Kinase Inhibitors 2020
JGB Pedreira, P Nahidino, M Kudolo, T Pantsar, BT Berger, M Forster, S Knapp, **S Laufer**, EJ Barreiro
Journal of Medicinal Chemistry 63 (13), 7347-7354

520 Antimicrobial and antileukemic effects: in vitro activity of *Calyptranthes grandifolia* aqueous leaf extract 2020
F Majolo, S Bitencourt, B Wissmann Monteiro, G Viegas Haute, C Alves, J Silva, S Pinteus, RC Vianna Santos, HF Vieira Torquato, EJ Paredes-Gamero, JR Oliveira, CF Volken De Souza, RF Pinto Pedrosa, **S Laufer**, MI Goettert

Journal of Toxicology and Environmental Health, Part A 83 (8), 289-301

519 Structural basis for EGFR mutant inhibition by trisubstituted imidazole inhibitors 2020
DE Heppner, M Günther, F Wittlinger, **SA Laufer**, MJ Eck
Journal of Medicinal Chemistry 63 (8), 4293-4305

518 The Investigation of Lipoxygenases as Therapeutic Targets in Malignant Pleural Mesothelioma 2020
L Oguh-Olayinka, V Agarwal, D Ranatunge, A Campbell, **S Laufer**, L Cawkwell, MJ Lind
Pathology & Oncology Research 26 (2), 985-995

517 Mapping the S1 and S1'subsites of cysteine proteases with new dipeptidyl nitrile inhibitors as trypanocidal agents 2020
L Cianni, C Lemke, E Gilberg, C Feldmann, F Rosini, FR Rocho, JFR Ribeiro, DY Tezuka, CD Lopes, S de Albuquerque, J Bajorath, **S Laufer**, A Leitao, M Gütschow, CA Montanari
PLoS Neglected Tropical Diseases 14 (3), e0007755

516 Promiscuity analysis of a kinase panel screen with designated p38 alpha inhibitors 2020
M González-Medina, F Miljković, GS Haase, P Drueckes, J Trappe, **S Laufer,** J Bajorath
European Journal of Medicinal Chemistry 187, 112004

515 P139 EFFECT OF LYSOSOMAL SHORT CHAIN FATTY ACID DELIVERY ON IMMUNE RESPONSE 2020
S Strass, C Heinzel, N Cloos, M Keppler, J Guse, M Burnet, **S Laufer**
Inflammatory Bowel Diseases 26 (Supplement_1), S12-S12

514 P139 EFFECT OF LYSOSOMAL SHORT CHAIN FATTY ACID DELIVERY ON IMMUNE RESPONSE 2020
S Strass, C Heinzel, N Cloos, M Keppler, J Guse, M Burnet, **S Laufer**
Gastroenterology 158 (3), S20

513 Sorafenib activity and disposition in liver cancer does not depend on organic cation transporter 1 2020
M Chen, C Neul, E Schaeffeler, F Frisch, S Winter, M Schwab, H Koepsell, S Hu, **S Laufer**, SD Baker, A Sparreboom, AT Nies
Clinical Pharmacology & Therapeutics 107 (1), 227-237

512 *In vitro* activities of *Ceiba speciosa* (A.St.-Hil) Ravenna aqueous stem bark extract 2019
JA Dörr, S Bitencourt, L Bortoluzzi, C Alves, J Silva, S Stoll, S Pinteus, AA Boligon, RC Vianna Santos, **S Laufer**, R Pedrosa, MI Goettert
Natural Product Research 33 (23), 3441-3444

511 Evaluation of the therapeutic potential of the selective p38 MAPK inhibitor Skepinone-L and the dual p38/JNK 3 inhibitor LN 950 in experimental K/BxN serum transfer arthritis 2019

P Guenthoer, K Fuchs, G Reischl, L Quintanilla-Martinez, I Gonzalez-Menendez, **S Laufer**, BJ Pichler, M Kneiling
Inflammopharmacology 27 (6), 1217-1227

510 Discovery of potent p38α MAPK inhibitors through a funnel like workflow combining in silico screening and in vitro validation 2019
A Astolfi, M Kudolo, J Brea, G Manni, G Manfroni, D Palazzotti, S Sabatini, F Ceccetti, T Felicetti, R Cannalire, S Massari, O Tabarrini, MI Loza, F Fallarino, V Ceccetti, **SA Laufer**, ML Barreca
European Journal of Medicinal Chemistry 182, 111624

509 Fast iterative synthetic approach toward identification of novel highly selective p38 MAP kinase inhibitors 2019
S Röhm, BT Berger, M Schröder, A Chaikuad, R Winkel, KFW Hekking, JJC Benningshof, G Müller, R Tesch, M Kudolo, M Forster, **S Laufer**, S Knapp
Journal of Medicinal Chemistry 62 (23), 10757-10782

508 Visual aptamer-based capillary assay for ethanolamine using magnetic particles and strand displacement 2019
M Mahmoud, **S Laufer**, HP Deigner
Microchimica Acta 186 (11), 1-8

507 Pyridinylimidazoles as GSK3β inhibitors: the impact of tautomerism on compound activity via water networks 2019
F Heider, T Pantsar, M Kudolo, F Ansideri, A De Simone, L Pruccoli, T Schneider, MI Goettert, A Tarozzi, V Andrisano, **SA Laufer**, P Koch
ACS Medicinal Chemistry Letters 10 (10), 1407-1414

506 Targeting the r-spine: Design, synthesis, and biological evaluation of novel type I1/2 p38 alpha MAP kinase inhibitors with excellent selectivity, high potency, and prolonged target residence time. Implication for cancer- and CNS-applications 2019
S Laufer, H Wentsch, N Walter, M Laemmerhofer, R Buijsman, D Rauh, L Zender
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY 258

505 Pyridinylimidazoles as dual glycogen synthase kinase 3β/p38α mitogen-activated protein kinase inhibitors 2019
F Heider, F Ansideri, R Tesch, T Pantsar, U Haun, E Döring, M Kudolo, A Poso, W Albrecht, **SA Laufer**, P Koch
European Journal of Medicinal Chemistry 175, 309-329

504 Natural chromones as potential anti-inflammatory agents: Pharmacological properties and related mechanisms 2019
LCF Opretzka, RF do Espírito-Santo, OA Nascimento, LS Abreu, IM Alves, E Döring, MB Pereira Soares, E da Silva Velozo, **SA Laufer**, CF Villarreal
International Immunopharmacology 72, 31-39

503 Liver X receptor mediated lipotoxicity represents a treatment option for liver cancer 2019
R Rudalska, J Harbig, M Snaebjoernsson, L Taranets, F Heinzmann, S Zwirner, WC Hu, T Kronenberger, TW Kang, A Poso, **S Laufer**, M Rosenfeldt, NP Malek, B Pichler, N Popov, A Schulze, L Zender, D Dauch
Cancer Research 79 (13_Supplement), 4377-4377

502 Myricetin inhibits panel of kinases implicated in tumorigenesis 2019
S Stoll, S Bitencourt, **S Laufer**, M Inês Goettert
Basic & Clinical Pharmacology & Toxicology 125 (1), 3-7

501 Design, Synthesis and Biological Evaluation of 7-Chloro-9*H*-pyrimido[4,5-*b*]indole-based Glycogen Synthase Kinase-3β Inhibitors 2019
S Andreev, T Pantsar, F Ansideri, M Kudolo, M Forster, D Schollmeyer, **SA Laufer**, P Koch
Molecules 24 (12), 2331

500 Are peptides a solution for the treatment of hyperactivated JAK3 pathways? 2019
A Dullius, CM Rocha, **S Laufer**, CFV de Souza, MI Goettert
Inflammopharmacology 27 (3), 433-452

499 Data for homogeneous thermofluorimetric assays for ethanolamine using aptamers and a PCR instrument 2019
M Mahmoud, **S Laufer**, HP Deigner
Data in Brief 24, 103946

498 Adjunctive role of Calyptranthes tricona extract with probiotic Kluyveromyces marxianus on colorectal adenocarcinoma Caco-2 cells 2019
DM Kich, S Bitencourt, D Faleiro, SM Immich, DJ Marmitt, T Baldasso, G Viegas Haute, J Rodrigues de Oliveira, **S Laufer**, R Pedrosa, CF Volken de Souza, MI Goettert
Phytochemistry Letters 30, 1-5

497 An aptamer based thermofluorimetric assay for ethanolamine 2019
M Mahmoud, **S Laufer**, HP Deigner
Biochimie 158, 233-237

496 Selective targeting of JAK3 with new small molecular compounds 2019
J Holstein, M Forster, **S Laufer**, K Ghoreschi
EXPERIMENTAL DERMATOLOGY 28 (3), E72-E72

495 N^1-{4-[2-(Methylthio)-1*H*-imidazol-5-yl]pyridin-2-yl}benzene-1,4-diamine 2019
A El-Gokha, F Ansideri, S Andreev, D Schollmeyer, **S Laufer**, P Koch
Molbank 2019 (1), M1048

494 Synthesis and structure-activity-relationship of 3, 4-Diaryl-1H-pyrrolo [2, 3-b] pyridines as irreversible Inhibitors of mutant EGFR-L858R/T790M 2019
M Günther, J Laux, **S Laufer**

European Journal of Pharmaceutical Sciences 128, 91-96

493 JAK3 and p38 MAPK inhibitors regulates hepatocellular carcinoma proliferation 2019
M Goettert, T Schneider, **S Laufer**
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY
392, S51-S51

492 A smartphone readout system for gold nanoparticle-based lateral flow assays: Application to monitoring of digoxigenin 2019
C Ruppert, N Phogat, **S Laufer**, M Kohl, HP Deigner
Microchimica Acta 186 (2), 1-9
Electronic Supplementary Material (ESM) on "A Smartphone readout…"

491 Sorafenib therapy for treatment of liver cancer is independent from organic cation transporter 1 (OCT1/SLC22A1) 2019
M Chen, C Neul, E Schaeffeler, F Frisch, S Winter, M Schwab, H Koepsell, S Hu, **S Laufer**, SD Baker, A Sparreboom, AT Nies
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY
392, S17-S18

490 A novel scaffold for EGFR inhibition: introducing N-(3-(3-phenylureido) quinoxalin-6-yl) acrylamide derivatives 2019
DN do Amaral, J Lategahn, HH Fokoue, EMB da Silva, CMR Sant'Anna, D Rauh, EJ Barreiro, **S Laufer**, L Moreira Lim
Scientific Reports 9 (1), 1-12
Supplementary Material on "A novel Scaffold for EGFR…"

489 Cysteine-type cathepsins promote the effector phase of acute cutaneous delayed-type hypersensitivity reactions 2019
J Schwenck, A Maurer, B Fehrenbacher, R Mehling, P Knopf, N Mucha, D Haupt, K Fuchs, CM Grissinger, D Bukala, J Holstein, M Schaller, I Gozalez Menendez, K Ghoreschi, L Quintanilla-Martinez, M Gütschow, **S Laufer**, T Reinheckel, M Röcken, H Kalbacher, BJ Pichler, M Kneiling
Theranostics 9 (13), 3903

488 Emerging and re-emerging warheads for targeted covalent inhibitors: applications in medicinal chemistry and chemical biology 2018
M Gehringer, **SA Laufer**
Journal of Medicinal Chemistry 62 (12), 5673-5724

487 In vitro activities of Ceiba speciose (A.St.-Hil) Ravenna aqueous stem bark extract 2018
JA Dörr, S Bitencourt, L Bortoluzzi, C Alves, J Silva, SN Stoll, SF Goncalves Pinteus, A Augusti Boligon, RC Vianna Santos, **S Laufer**, R Pedrosa, MI Goettert
Natural Product Research 33 (46): 1-4

486 Donated chemical probes for open science: Shown here are target and compound related criteria applied by the Structural Genomics Consortium. 2018
S. Müller, S Ackloo, CH Arrowsmith, M Bauser, JL Baryza, J Blagg, J

Böttcher, C Bountra, PJ Brown, ME Bunnage, AJ Carter, D Damerell, V Dötsch, DH Drewry, AM Edwards, J Edwards, JM Elkins, C Fischer, SV Frye, A Gollner, C Grimshaw, A IJzerman, T Hanke, IV Hartung, S Hitchcock, T Howe, TV Hughes, **S Laufer**, V Li, S Liras, BD Marsden, H Matsui, J Mathias, RC O'Hagan, DR Owen, V Pande, D Rauh, SH Rosenberg, B Roth, N Schneider, C Scholten, KS Saikatendu, A Simeonov, M Takizawa, C Tse, PR Thompson, DK Treiber, AY Viana, CI Wells, TM Willson, WJ Zuercher, S Knapp, A Mueller-Fahrnow
eLife Sciences 7

485 Substituted benzamides from anti-inflammatory and p38 kinase inhibitors to antitubercular activity: design, synthesis and screening 2018
R Kulkarni, U Mitkari, G Achaiah, **S Laufer**, D Bikshapti, VM Chandrashekar, PB Gurav, SJ Joshi, VD Chipade
Mini Reviews in Medicinal Chemistry 18 (17), 1486-1497

484 Kinase inhibitors 2018
P Koch, **S Laufer**
Molecules 23 (7), 1818

483 Structural Optimization of a Pyridinylimidazole scaffold: shifting the selectivity from p38α mitogen-activated protein kinase to c-Jun N-terminal kinase 3 2018
F Ansideri, JT Macedo, M Eitel, A El-Gokha, DS Zinad, C Scarpellini, M Kudolo, D Schollmeyer, FM Boeckler, BS Blaum, **SA Laufer**, P Koch
ACS Omega 3 (7), 7809-7831

482 NB 06: From a simple lysosomotropic aSMase inhibitor to tools for elucidating the role of lysosomes in signaling apoptosis and LPS-induced inflammation 2018
M Blaess, N Bibak, RA Claus, M Kohl, GA Bonaterra, R Kinscherf, **S Laufer**, HP Deigner
European Journal of Medicinal Chemistry 153, 73-104

481 Development, Optimization, and Structure–Activity Relationships of Covalent-Reversible JAK3 Inhibitors Based on a Tricyclic Imidazo[5,4-*d*]pyrrolo[2,3-*b*]pyridine scaffold 2018
M Forster, A Chaikuad, T Dimitrov, E Döring, J Holstein, BT Berger, M Gehringer, K Ghoreschi, S Müller, S Knapp, **SA Laufer**
Journal of Medicinal Chemistry 61 (12), 5350-5366

480 The cysteinome of protein kinases as a target in drug development 2018
A Chaikuad, P Koch, **SA Laufer**, S Knapp
Angewandte Chemie International Edition 57 (16), 4372-4385

479 Das Cysteinom der Proteinkinasen als Zielstruktur in der Arzneistoffentwicklung 2018
A Chaikuad, P Koch, **SA Laufer**, S Knapp
Angewandte Chemie 130 (16), 4456-4470

478 A Diverse and Versatile Regiospecific Synthesis of Tetrasubstituted Alkylsulfanylimidazoles as p38α Mitogen-Activated Protein Kinase Inhibitors 2018
F Ansideri, S Andreev, A Kuhn, W Albrecht, **SA Laufer**, P Koch
Molecules 23 (1), 221

477 Donated chemical probes for open science 2018
S Müller, S Ackloo, CH Arrowsmith, M Bauser, JL Baryza, J Blagg, J Böttcher, C Bountra, PJ Brown, ME Bunnage, AJ Carter, D Damerell, V Dötsch, DH Drewry, AM Edwards, J Edwards, JM Elkins, C Fischer, SV Frye, A Gollner, CE Grimshaw, A IJzerman, T Hanke, IV Hartung, S Hitchcock, T Howe, TV Hughes **S Laufer**,VMJ Li, S Liras, BD Marsden, H Matsui, J Mathias, RC O'Hagan, DR Owen, V Pande, D Rauh, SH Rosenberg, BL Roth, NS Schneider, C Scholten, KS Saikatendu, A Simeonov, M Taikizawa, C Tse, PR Thompson, DK Treiber, AY Viana, CI Wells, TM Wilson, WJ Zuercher, S Knapp, A Müller-Fahrnow
eLife 7

476 Abstract B167: KRAS gene mutations are associated with tumor resistance toward the LN1222/AD736 p38 inhibitor 2018
V Vuaroqueaux, G Kelter, HR Hendriks, **S Laufer**, HH Fiebig
Molecular Cancer Therapeutics 17 (1_Supplement), B167-B167

475 Synthesis, X-ray diffraction study and pharmacological evaluation of 3-amino-4-methylthiophene-2-acylcarbohydrazones 2018
S Herrmann, T Schübel, FN Costa, MLC Barbosa, FF Ferreira, TLMF Dias, MV Araujo, MS Alexandre-Moreira, LM Lima, **S Laufer**, EJ Barreiro
Anais da Academia Brasileira de Ciências 90, 1073-1088

474 Neue Anwendungen der Klick-Chemie in Zellbiologie und Wirkstoffentwicklung 2017
M Gehringer, **SA Laufer**
Angewandte Chemie 129 (49), 15709-15711

473 Click chemistry: Novel applications in cell biology and drug discovery 2017
M Gehringer, **SA Laufer**
Angewandte Chemie International Edition 56 (49), 15504-15505

472 P38 Kinase, SGK1 and NF-κB Dependent Up-Regulation of Na+/Ca2+ Exchanger Expression and Activity Following TGFß1 Treatment of Megakaryocytes 2017
T Al-Maghout, L Pelzl, I Sahu, B Sukkar, Z Hosseinzadeh, R Gutti, **S Laufer**, J Voelkl, B Pieske, M Gawaz, F Lang
Cellular Physiology and Biochemistry 42 (6), 2169-2181

471 From 2-alkylsulfanylimidazoles to 2-alkylimidazoles: an approach towards metabolically more stable p38α MAP kinase inhibitors 2017
F Heider, U Haun, E Döring, M Kudolo, C Sessler, W Albrecht, **S Laufer**, P Koch
Molecules 22 (10), 1729

470 Design, Synthesis, and Biological Evaluation of Novel Type I½ p38α MAP Kinase Inhibitors with Excellent Selectivity, High Potency, and Prolonged Target … 2017
NM Walter, HK Wentsch, M Bührmann, SM Bauer, E Döring, S Mayer-Wrangowski, A Sievers-Engler, N Willemsen-Seegers, G Zaman, R Buijsman, M Lämmerhofer, D Rauh, **SA Laufer**
Journal of medicinal chemistry 60 (19), 8027-8054

469 Recent advances in JAK3 inhibition: Isoform selectivity by covalent cysteine targeting 2017
M Forster, M Gehringer, **SA Laufer**
Bioorganic & medicinal chemistry letters 27 (18), 4229-4237

468 EGFR triple mutant: Recent set-backs and new hopes in fighting mutant non-small cell lung cancer 2017
S Laufer, M Guenther, M Juchum, E Doering, M Keul, J Lategahn, H Tumbrink, J Engel, D Rauh
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY 254

467 Progress towards a public chemogenomic set for protein kinases and a call for contributions 2017
DH Drewry, CI Wells, DM Andrews, R Angell, H Al-Ali, AD Axtman, SJ Capuzzi, JM Elkins, P Ettmayer, M Frederiksen, O Gileadi, N Gray, A Hooper, S Knapp, **S Laufer**, U Luecking, M Michaelides, S Müller, E Muratov, RA Denny, KS Saikatendu, DK Treiber, WJ Zuercher, TM Wilson
PloS one 12 (8), e0181585

466 Androgen-mediated sex bias impairs efficiency of leukotriene biosynthesis inhibitors in males 2017
S Pace, C Pergola, F Dehm, A Rossi, J Gerstmeier, F Troisi, H Pein, AM Schaible, C Weinigel, S Rummler, H Northoff, **S Laufer**, TJ Maier, O Radmark, B Samuelsson, A Koeberle, L Sautebin, O Werz
The Journal of clinical investigation 127 (8), 3167-3176

465 Discovery of *N*-{4-[5-(4-Fluorophenyl)-3-methyl-2-methylsulfanyl-3*H*-imidazol-4-yl]-pyridin-2-yl}-acetamide (CBS-3595), a Dual p38α MAPK/PDE-4 Inhibitor with … 2017
W Albrecht, A Unger, SM Bauer, **SA Laufer**
Journal of Medicinal Chemistry 60 (13), 5290-5305

464 Trisubstituted pyridinylimidazoles as potent inhibitors of the clinically resistant L858R/T790M/C797S EGFR mutant: targeting of both hydrophobic regions and the phosphate … 2017
M Gunther, J Lategahn, M Juchum, E Doring, M Keul, J Engel, HL Tumbrink, D Rauh, **S Laufer**
Journal of medicinal chemistry 60 (13), 5613-5637

463 Proteasome activation by small molecules 2017
Y Leestemaker, A de Jong, KF Witting, R Penning, K Schuurman, B Rodenko, EA Zaal, B van de Kooij, **S Laufer** AJR Heck, J Borst, W Scheper, CR Berkers, H Ovaa
Cell chemical biology 24 (6), 725-736. e7

462 Trisubstituted imidazoles with a rigidized hinge binding motif act as single digit nM inhibitors of clinically relevant EGFR L858R/T790M and L858R/T790M/C797S mutants: an … 2017
M Juchum, M Günther, E Döring, A Sievers-Engler, M Lämmerhofer, **S Laufer**
Journal of medicinal chemistry 60 (11), 4636-4656

461 Optimierte Bindungsdauer am Zielenzym: Typ-I-Inhibitoren der p38α-MAP-Kinase mit verbesserter Bindungskinetik durch direkte Interaktion mit der R-Spine 2017
HK Wentsch, NM Walter, M Bührmann, S Mayer-Wrangowski, D Rauh, GJR Zaman, N Willemsen-Seegers, RC Buijsman, M Henning, D Dauch, L Zender, **S Laufer**
Angewandte Chemie 129 (19), 5448-5453

460 Optimized Target Residence Time: Type I Inhibitors for p38α MAP Kinase with Improved Binding Kinetics through Direct Interaction with the R-Spine 2017
HK Wentsch, NM Walter, M Bührmann, S Mayer-Wrangowski, D Rauh, GJR Zaman, N Willemsen-Seegers, RC Buijsman, M Henning, D Dauch, L Zender, **S Laufer**
Angewandte Chemie International Edition 56 (19), 5363-5367

459 In vivo hypoxia PET imaging quantifies the severity of arthritic joint inflammation in line with overexpression of hypoxia-inducible factor and enhanced reactive oxygen species … 2017
K Fuchs, A Kuehn, M Mahling, P Guenthoer, A Hector, J Schwenck, D Hartl, **S Laufer**, U Kohlhofer, L Quintanilla-Martinez, G Reischl, M Röcken, BJ Pichler, M Kneiling
Journal of Nuclear Medicine 58 (5), 853-860

458 In vivo hypoxia PET imaging quantifies the severity of arthritic joint inflammation in line with overexpression of HIF and enhanced ROS generation 2017
K Fuchs, A Kuehn, M Mahling, P Guenthoer, A Hector, D Hartl, **S Laufer**, U Kohlhofer, L Quintanilla-Martinez, G Reischl, M Röcken, BJ Pichler, M Kneiling
Journal of Nuclear Medicine

457 Tri-and tetrasubstituted pyridinylimidazoles as covalent inhibitors of c-Jun N-terminal kinase 3 2017
F Muth, A El-Gokha, F Ansideri, M Eitel, E Döring, A Sievers-Engler, A Lange, FM Boeckler, M Lämmerhofer, P Koch, **SA Laufer**
Journal of Medicinal Chemistry 60 (2), 594-607

456 Are Two Better Than One in Rheumatoid Arthritis? Development of Dual p38α MAPK/PDE-4 Inhibitors for Treatment of TNFα-Driven Diseases 2017
W Albrecht, SM Bauer, **SA Laufer**
Elsevier

455 Multi-gram Preparation of 7-Nitroquinoxalin-2-amine 2017
DN Amaral, FR Alves, EJ Barreiro, **SA Laufer,** LM Lima
Journal of the Brazilian Chemical Society 28, 1874-1878

454 Neuromodulatory effects of Calyptranthes grandifolia extracts against 6-hydroxydopamine-induced neurotoxicity in SH-SY5Y cells 2016
DM Kich, S Bitencourt, C Alves, J Silva, S Pinteus, R Pedrosa, **S Laufer**, CF Volken de Souza, MI Goettert
Biomedicine & Pharmacotherapy 84, 382-386

453 IL-1β, IL-18, and eicosanoids promote neutrophil recruitment to pore-induced intracellular traps following pyroptosis 2016
I Jorgensen, JP Lopez, **SA Laufer**, EA Miao
European journal of immunology 46 (12), 2761-2766

452 Selective JAK3 inhibitors with a covalent reversible binding mode targeting a new induced fit binding pocket 2016
M Forster, A Chaikuad, SM Bauer, J Holstein, MB Robers, CR Corona, M Gehringer, E Pfaffenrot, K Ghoreschi, S Knapp, **SA Laufer**
Cell chemical biology 23 (11), 1335-1340

451 Impact of membrane drug transporters on resistance to small-molecule tyrosine kinase inhibitors 2016
C Neul, E Schaeffeler, A Sparreboom, **S Laufer**, M Schwab, AT Nies
Trends in pharmacological sciences 37 (11), 904-932

450 Tofacitinib and analogs as inhibitors of the histone kinase PRK1 (PKN1) 2016
D Ostrovskyi, T Rumpf, J Eib, A Lumbroso, I Slynko, S Klaeger, S Heinzlmeir, M Forster, M Gehringer, E Pfaffenrot, SM Bauer, K Schmidtkunz, S Wenzler, E Metzger, B Kuster, S **Laufer**, R Schüle, W Sippl, B Breit, M Jung
Future Medicinal Chemistry 8 (13), 1537-1551

449 Lungenkrebs: EGFR-Inhibitoren mit hoher Wirksamkeit gegen die therapieresistente L858R/T790M/C797S-Mutante. 2016
M Günther, M Juchum, G Kelter, H Fiebig, **S Laufer**
Angewandte Chemie 128 (36), 11050-11054

448 Lung cancer: EGFR inhibitors with low nanomolar activity against a therapy-resistant L858R/T790M/C797S mutant 2016
M Günther, M Juchum, G Kelter, H Fiebig, **S Laufer**
Angewandte Chemie International Edition 55 (36), 10890-10894

447 Why antidiabetic vanadium complexes are not in the pipeline of "big pharma" drug research? A critical review 2016
T Scior, J Antonio Guevara-Garcia, QT Do, P Bernard, **S Laufer**

Current medicinal chemistry 23 (25), 2874-2891

446 Stimulating effect of sclareol on suicidal death of human erythrocytes 2016
E Signoretto, **SA Laufer,** F Lang
Cellular Physiology and Biochemistry 39 (2), 554-564

445 Poly [[tetramethanolbis [4-oxo-3-(pyridin-4-yl)-1-(2, 4, 6-trichlorophenyl)-4, 5-dihydro-1H-pyrazolo [3, 4-d] pyrimidin-6-olato] disodium]–diethyl ether–methanol (1/1/2)] 2016
B Abu Thaher, D Schollmeyer, **S Laufer**
IUCrData 1 (7), x161081

444 A MYC-Aurka protein complex represents an actionable target in p53 altered liver cancer 2016
D Daniel, R Rudalska, G Cossa, JC Nault, S Imbeaud, NP Malek, T Longerich, **S Laufer**, A Poso, J Zucman-Rossi, M Eilers, L Zender
Cancer Research 76 (14_Supplement), 1257-1257

443 Evaluation of organic cation transporter 1 (OCT1, SLC22A1) as transporter for sorafenib 2016
C Neul, SD Baker, A Sparreboom, E Schaeffeler, **S Laufer**, M Schwab, AT Nies
Cancer Research 76 (14_Supplement), 257-257

442 Design and Development of Microsomal Prostaglandin E_2 Synthase-1 Inhibitors: Challenges and Future Directions 2016
A Koeberle, **SA Laufer**, O Werz
Journal of medicinal chemistry 59 (13), 5970-5986

441 Spinal inhibition of p38 MAP kinase reduces inflammatory and neuropathic pain in male but not female mice: Sex-dependent microglial signaling in the spinal cord 2016
S Taves, T Berta, DL Liu, S Gan, G Chen, YH Kim, T Van de Ven, **S Laufer**, RR Ji
Brain, behavior, and immunity 55, 70-81

440 SCISSOR—Spinal Cord Injury Study on Small molecule-derived Rho inhibition: a clinical study protocol 2016
MA Kopp, T Liebscher, R Watzlawick, P Martus, **S Laufer**, C Blex, R Schindler, GJ Jungehulsing, S Knüppel, M Kreutzträger, A Ekkernkamp, U Dirnagl, SM Strittmatter, A Niedeggen, JM Schwab
BMJ open 6 (7), e010651

439 A MYC–aurora kinase A protein complex represents an actionable drug target in p53-altered liver cancer 2016
D Dauch, R Rudalska, G Cossa, JC Nault, TW Kang, T Wuestefeld, A Hohmeyer, S Imbeaud, T Yevsa, L Hoenicke, T Pantsar, P Bozko, NP Malek, T Longerich, **S Laufer**, A Poso, J Zucman-Rossi, M Eilers, L Zender
Nature medicine 22 (7), 744-753

438 Fine-tuned PEGylation of chitosan to maintain optimal siRNA-nanoplex bioactivity 2016
A Guţoaia, L Schuster, S Margutti, **S Laufer**, B Schlosshauer, R Krastev, D Stoll, H Hartmann
Carbohydrate polymers 143, 25-34

437 Salinomycin, a candidate drug for the salinomycin, a candidate drug for the elimination of cancer stem cells elimination of cancer stem cells 2016
C Naujokat, **S Laufer**
Role of Cancer Stem Cells in Cancer Biology and Therapy 227

436 Fine-tuned PEGylation of chitosan to maintain optimal siRNA-nanoplex bioactivity 2016
B Schlosshauer, D Stoll, H Hartmann, L Schuster, R Krastev, S Margutti, **S Laufer**
Carbohydrate polymers 143

435 From enzyme to whole blood: sequential screening procedure for identification and evaluation of p38 MAPK inhibitors 2016
SM Bauer, JM Kubiak, U Rothbauer, **S Laufer**
Kinase Screening and Profiling: Methods and Protocols, 123-148

434 Fucoxanthin induced suicidal death of human erythrocytes 2015
M Briglia, S Calabró, E Signoretto, K Alzoubi, **S Laufer**, C Faggio, F Lang
Cellular Physiology and Biochemistry 37 (6), 2464-2475

433 Targeting the gatekeeper MET146 of C-Jun N-terminal kinase 3 induces a bivalent halogen/chalcogen bond 2015
A Lange, M Günther, FM Büttner, MO Zimmermann, J Heidrich, S Hennig, S Zahn, C Schall, a Sievers-Engler, F Ansideri, P Koch, M Laemmerhofer, T Stehle, **SA Laufer**, FM Boeckler
Journal of the American Chemical Society 137 (46), 14640-14652

432 The Pyrazolobenzothiazine Core as a New Chemotype of p38 Alpha Mitogen-Activated Protein Kinase Inhibitors 2015
S Sabatini, G Manfroni, ML Barreca, SM Bauer, M Gargaro, R Cannalire, A Astolfi, J Brea, C Vacca, M Pirro, S Massari, O Tabarrini, MI Loza, F Fallarino, **SA Laufer**, V Cecchetti
Chemical biology & drug design 86 (4), 531-545

431 Triggering of suicidal erythrocyte death by ruxolitinib 2015
M Briglia, A Fazio, C Faggio, **S Laufer**, K Alzoubi, F Lang
Cellular Physiology and Biochemistry 37 (2), 768-778

430 c-Jun *N*-terminal kinase inhibitors: a patent review (2010 – 2014) 2015
M Gehringer, F Muth, P Koch, **SA Laufer**
Expert opinion on therapeutic patents 25 (8), 849-872

429 Anti-inflammatory activities of phenoxyphenyl ureas mediated by inhibition of p38 kinase 2015

R Kulkarni, S Diwyani, **S Laufer**, C VM, P Gurav, P Habbu
Current Enzyme Inhibition 11 (2), 116-123

428 Impact of p38 MAP kinase inhibitors on LPS-induced release of TNF-α in whole blood and primary cells from different species 2015
S Fehr, A Unger, E Schaeffeler, S Herrmann, **S Laufer**, M Schwab, W Albrecht
Cellular Physiology and Biochemistry 36 (6), 2237-2249

427 Triggering of suicidal erythrocyte death following boswellic acid exposure 2015
S Calabrò, K Alzoubi, C Faggio, **S Laufer**, F Lang
Cellular Physiology and Biochemistry 37 (1), 131-142

426 New insights into novel inhibitors against deoxyhypusine hydroxylase from Plasmodium falciparum: compounds with an iron chelating potential 2015
I von Koschitzky, H Gerhardt, M Lämmerhofer, M Kohout, M Gehringer, **S Laufer**, M Pink, S Schmitz-Spanke, C Strube, A Kaiser
Amino Acids 47, 1155-1166

425 Role of p38 mitogen-activated protein kinase in linking stearoyl-CoA desaturase-1 activity with endoplasmic reticulum homeostasis 2015
A Koeberle, C Pergola, H Shindou, SC Koeberle, T Shimizu, **SA Laufer**, O Werz
The FASEB Journal 29 (6), 2439-2449

424 Effect of TGFβ on calcium signaling in megakaryocytes 2015
J Yan, E Schmid, A Almilaji, E Shumilina, O Borst, **S Laufer,** M Gawaz, F Lang
Biochemical and Biophysical Research Communications 461 (1), 8-13

423 Fighting cancer drug resistance: Opportunities and challenges for mutation-specific EGFR inhibitors 2015
M Juchum, M Günther, **SA Laufer**
Drug Resistance Updates 20, 12-28

422 Influence of annexin A7 on insulin sensitivity of cellular glucose uptake 2015
D Luo, A Fajol, AT Umbach, AA Noegel, **S Laufer,** F Lang, M Föller
Pflügers Archiv-European Journal of Physiology 467, 641-649

421 Proteinkinase-Inhibitoren: selektiv und wirksam 2015
A Freitag, **S Laufer**
Nachrichten aus der Chemie 63 (4), 420-425

420 Flavonoids inhibit COX-1 and COX-2 enzymes and cytokine/chemokine production in human whole blood 2015
D Ribeiro, M Freitas, SM Tomé, AMS Silva, **S Laufer**, JLFC Lima, E Fernandes
Inflammation 38, 858-870

419 Solution-phase parallel synthesis of Ruxolitinib-derived Janus kinase inhibitors via copper-catalyzed Azide–Alkyne cycloaddition 2015

M Gehringer, M Forster, **SA Laufer**
ACS Combinatorial Science 17 (1), 5-10

418 *Tetra*-Substituted Pyridinylimidazoles As Dual Inhibitors of p38α Mitogen-Activated Protein Kinase and c-Jun *N*-Terminal Kinase 3 for Potential Treatment of … 2015
F Muth, M Günther, SM Bauer, E Döring, S Fischer, J Maier, P Drückes, J Köppler, J Trappe, U Rothbauer, P Koch, **SA Laufer**
Journal of medicinal chemistry 58 (1), 443-456

417 Advancing the kinase field: new targets and second generation inhibitors 2015
S Laufer, J Bajorath
Journal of Medicinal Chemistry 58 (1), 1-1

416 Development of first lead structures for phosphoinositide 3-kinase-C2γ inhibitors 2015
A Freitag, P Prajwal, A Shymanets, C Harteneck, B Nürnberg, C Schächtele, M Kubbutat, F Trotzke, **SA Laufer**
Journal of medicinal chemistry 58 (1), 212-221

415 Inhibitors of c-Jun N-terminal kinases: an update 2015
P Koch, M Gehringer, **SA Laufer**
Journal of medicinal chemistry 58 (1), 72-95

414 New Frontiers in Kinases: Second Generation Inhibitors–Going beyond Cancer 2015
S Laufer
ACS Medicinal Chemistry Letters 6 (1), 1-1

413 An optimized and versatile synthesis to pyridinylimidazole-type p38α mitogen activated protein kinase inhibitors 2015
A El-Gokha, **SA Laufer**, P Koch
Organic & Biomolecular Chemistry 13 (43), 10699-10704

412 Design and synthesis of novel quinazoline derivatives and their evaluation as PI3Ks inhibitors 2014
OM El-Said, MM Hamed, **S Laufer**, AH Abadi
Chemical and Pharmaceutical Bulletin 62 (12), 1166-1172

411 Antinociceptive, anti-inflammatory and gastroprotective effects of a hydroalcoholic extract from the leaves of Eugenia punicifolia (Kunth) DC. in rodents 2014
RT Basting, CM Nishijima, JA Lopes, RC Santos, LL Périco, **S Laufer**, S Bauer, MF Costa, LC Santos, LRM Rocha, W Vilegas, ARS Santos, C Dos Santos, CA Hiruma-Lima
Journal of ethnopharmacology 157, 257-267

410 Novel Hinge-Binding Motifs for Janus Kinase 3 Inhibitors: A Comprehensive Structure–Activity Relationship Study on Tofacitinib Bioisosteres 2014

M Gehringer, M Forster, E Pfaffenrot, SM Bauer, **SA Laufer**
ChemMedChem 9 (11), 2516-2527

409 Anti-inflammatory macrolides to manage chronic neutrophilic inflammation 2014
M Burnet, JH Guse, HJ Gutke, L Guillot, **S Laufer,** U Hahn, MP Seed, E Vallejo, M Eggers, D McKenzie, W Albrecht, MJ Parnham
Macrocycles in Drug Discovery, 206-234

408 Monitoring of therapeutic Cathepsin B inhibition of in vivo by a specific activateable optical probe and ex vivo by active site labeling 2014
J Schwenck, A Maurer, K Fuchs, CM Griessinger, D Bukala, H Kalbacher, B Fehrenbacher, **S Laufer**, M Roecken, C la Fougere, BJ Pichler, M Kneilling
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING 41, S411-S412

407 *In vivo* RNAi screening identifies a mechanism of sorafenib resistance in liver cancer 2014
R Rudalska, D Dauch, T Longerich, K McJunkin, T Wuestefeld, TW Kang, A Hohmeyer, M Pesic, J Leibold, A Von Thun, P Schirmacher, J Zuber, KH Weiss, S Powers, NP Malek, M Eilers, B Sipos, SW Lowe, R Geffers, **S Laufer**, L Zender
Nature medicine 20 (10), 1138-1146

406 Effect of TGFβ on Na+/K+ ATPase activity in megakaryocytes 2014
Z Hosseinzadeh, E Schmid, E Shumilina, **S Laufer**, O Borst, M Gawaz, F Lang
Biochemical and Biophysical Research Communications 452 (3), 537-541

405 Compostos 2-cloro-4-anilinoquinazolinicos inibidores de proteínas Tirosina cinases, composições farmacêuticas compreendendo os mesmos, processo para sua produção e método para … 2014
CMR Sant'Anna, EJL Barreiro, LM Lima, MLC Barbosa, R Tesch, **SA Laufer**
Brasil

404 C-Jun N-terminal kinase 3 (JNK3) as target for halogen bonding 2014
A Lange, M Guenther, **SA Laufer**, FM Boeckler
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY 248

403 Modeling of compound profiling experiments using support vector machines 2014
J Balfer, K Heikamp, **S Laufer**, J Bajorath
Chemical Biology & Drug Design 84 (1), 75-85

402 Discovery of a Novel Series of Tetrahydro-β-carbolines Inducing Autophagic Cell Death in Human Metastatic Melanoma 2014
NS Ahmed, M Elgendy, **S Laufer**, AH Abadi
Archiv der Pharmazie 347 (6), 398-406

401 Four New Flavonol Glycosides from the Leaves of *Brugmansia suaveolens* 2014
F Geller, R Murillo, L Steinhauser, B Heinzmann, K Albert, I Merfort, **S Laufer**
Molecules 19 (5), 6727-6736

400 Extract from gum resin of Boswellia serrata decreases [IA. sub. 2]-antibody in a patient with" Late onset Autoimmune Diabetes of the Adult"(LADA) 2014
E Schrott, **S Laufer**, M Lammerhofer, HPT Ammon
Phytomedicine: International Journal of Phytotherapy & Phytopharmacology 21

399 p38 MAPK inhibitors: a patent review (2012–2013) 2014
S Bühler, **SA Laufer**
Expert opinion on therapeutic patents 24 (5), 535-554

398 A p38 substrate-specific MK2-EGFP translocation assay for identification and validation of new p38 inhibitors in living cells: a comprising alternative for acquisition of … 2014
R Anton, SM Bauer, PR Keck, **S Laufer**, U Rothbauer
PloS one 9 (4), e95641

397 2-(3-{(3R, 4R)-4-Methyl-3-[methyl (7H-pyrrolo [2, 3-d] pyrimidin-4-yl) amino] piperidin-1-yl} oxetan-3-yl) acetonitrile monohydrate 2014
M Gehringer, E Pfaffenrot, P Keck, D Schollmeyer, **SA Laufer**
Acta Crystallographica Section E: Structure Reports Online 70 (4), o382-o383

396 New frontiers in kinases: second generation inhibitors 2014
S Laufer, J Bajorath
Journal of Medicinal Chemistry 57 (6), 2167-2168

395 Interference of boswellic acids with the ligand binding domain of the glucocorticoid receptor 2014
T Scior, M Verhoff, I Gutierrez-Aztatzi, HPT Ammon, **S Laufer**, O Werz
Journal of chemical information and modeling 54 (3), 978-986

394 Specific inhibition of p38-MAPK signaling suppresses experimental arthritis and inflammation induced hypoxia 2014
P Guenthoer, K Fuchs, D Lamparter, G Reischl, S Aidone, M Koenig, **S Laufer**, M Roecken, BJ Pichler, M Kneilling
EXPERIMENTAL DERMATOLOGY 23 (3), E29-E29

393 Efficacy and gastrointestinal tolerability of ML3403, a selective inhibitor of p38 MAP kinase and CBS-3595, a dual inhibitor of p38 MAP kinase and phosphodiesterase 4 in CFA … 2014
DA Koch, RBM Silva, AH de Souza, CE Leite, NF Nicoletti, MM Campos, **S Laufer**, FB Morrone
Rheumatology 53 (3), 425-432

392 Back Cover: Design and Synthesis of Tricyclic JAK3 Inhibitors with Picomolar Affinities as Novel Molecular Probes (ChemMedChem 2/2014) 2014
M Gehringer, E Pfaffenrot, S Bauer, **SA Laufer**
ChemMedChem 9 (2), 412-412

391 Design and synthesis of tricyclic JAK3 inhibitors with picomolar affinities as novel molecular probes 2014
M Gehringer, E Pfaffenrot, S Bauer, **SA Laufer**
ChemMedChem 9 (2), 277-281

390 Dibenzocycloheptatone derivatives and pharmaceutical agents containing said compounds 2014
S Laufer, W Albrecht
US Patent 8,633,312

389 Novel 2-chloro-4-anilino-quinazoline derivatives as EGFR and VEGFR-2 dual inhibitors 2014
ML de Castro Barbosa, LM Lima, R Tesch, CMR Sant'Anna, F Totzke, MHG Kubbutat, C Schaechtele, **SA Laufer**, EJ Barreiro
European journal of medicinal chemistry 71, 1-14

388 Metabolism of a novel skepinone l-like p38 mitogen-activated protein kinase inhibitor 2014
K Storch, M Gehringer, B Baur, **SA Laufer**
MedChemComm 5 (6), 808-815

387 A direct enzyme-linked immunosorbent assay (ELISA) for the quantitative evaluation of Janus Kinase 3 (JAK3) inhibitors 2014
SM Bauer, M Gehringer, **SA Laufer**
Analytical Methods 6 (21), 8817-8822

386 Multiplex in vivo RNAi screening instructs combination therapies to increase the therapeutic efficacy of the multikinase inhibitor sorafenib 2014
R Rudalska, D Dauch, K McJunkin, TW Kang, T Wuestefeld, R Geffers, P Schirmacher, S Lowe, T Longerich, **S Laufer**, L Zender
Zeitschrift für Gastroenterologie 52 (01), P_4_31

385 A New *In Vitro* Model to Study Cellular Responses after Thermomechanical Damage in Monolayer Cultures 2013
A Hettler, S Werner, S Eick, **S Laufer**, F Weise
PLoS One 8 (12), e82635

384 *Entada africana* fraction CH_2Cl_2/MEOH 5% inhibits inducible nitric oxide synthase and pro-inflammatory cytokines gene expression induced by … 2013
BA Owona, NF Njayou, **SA Laufer**, HJ Schluesener, PF Moundipa
BMC Complementary and Alternative Medicine 13, 1-7

383 Metabolically Stable Dibenzo[*b*,*e*]oxepin-11(6*H*)-ones as Highly Selective p38 MAP Kinase Inhibitors: Optimizing Anti-Cytokine Activity in Human Whole Blood 2013

B Baur, K Storch, KE Martz, MI Goettert, A Richters, D Rauh, **SA Laufer**
Journal of medicinal chemistry 56 (21), 8561-8578

382 Effects of a Combined Cyclooxygenase/Lipoxygenase Inhibitor in Pancreatic Cancer 2013
HMA Kader, N Nalin, M El-Zeiry, **S Laufer,** TE Adrian
PANCREAS 42 (8), 1357-1357

381 Induction but not inhibition of COX-2 confers human lung cancer cell apoptosis by celecoxib 2013
R Ramer, U Walther, P Borchert, **S Laufer**, M Linnebacher, B Hinz
Journal of lipid research 54 (11), 3116-3129

380 Choline and tromethamine salt of licofelone 2013
W Albrecht, HG Striegel, **S Laufer**
US Patent 8,519,155

379 A fraction of stem bark extract of Entada africana suppresses lipopolysaccharide-induced inflammation in RAW 264.7 cells 2013
BA Owona, NF Njayou, **S Laufer**, PF Moundipa, HJ Schluesener
Journal of ethnopharmacology 149 (1), 162-168

378 Skepinone-L, a novel potent and highly selective inhibitor of p38 MAP kinase, effectively impairs platelet activation and thrombus formation 2013
O Borst, B Walker, P Münzer, A Russo, E Schmid, C Faggio, B Bigalke, **S Laufer**, M Gawaz, F Lang
Cellular Physiology and Biochemistry 31 (6), 914-924

377 tert-Butyl N-[(3R, 4R)-1-(2-cyanoacetyl)-4-methylpiperidin-3-yl]-N-methylcarbamate 2013
M Gehringer, M Forster, D Schollmeyer, **S Laufer**
Acta Crystallographica Section E: Structure Reports Online 69 (6), o935-o935

376 Drug discovery: a modern decathlon 2013
S Laufer, U Holzgrabe, D Steinhilber
Angewandte Chemie International Edition 52 (15), 4072-4076

375 Arzneistoffentwicklung, ein moderner Zehnkampf 2013
S Laufer, U Holzgrabe, D Steinhilber
Angewandte Chemie 125 (15), 4164-4168

374 Deoxyhypusine Hydroxylase from *Plasmodium vivax*, the Neglected Human Malaria Parasite: Molecular Cloning, Expression and Specific Inhibition by the 5-LOX … 2013
VA Atemnkeng, M Pink, S Schmitz-Spanke, XJ Wu, LL Dong, KH Zhao, C May, **S Laufer,** B Langer, A Kaiser
PLoS One 8 (3), e58318

373 Design, Synthesis and Characterization of N', N"-Diaryl Ureas as p38 Kinase Inhibitors 2013
R G Kulkarni, **S Laufer**, C Mangannavar, A Garlapati
Medicinal Chemistry 9 (2), 213-221

372 Salinomycin, a candidate drug for the elimination of cancer stem cells 2013
C Naujokat, **S Laufer**
Role of Cancer Stem Cells in Cancer Biology and Therapy

371 Arachidonoyl-phosphatidylcholine oscillates during the cell cycle and counteracts proliferation by suppressing Akt membrane binding 2013
A Koeberle, H Shindou, SC Koeberle, **SA Laufer,** T Shimizu, O Werz
Proceedings of the National Academy of Sciences 110 (7), 2546-2551

370 Targeting cancer stem cells with defined compounds and drugs 2013
C Naujokata, **S Laufer**
Journal of Cancer Research Updates 2 (1), 36-67

369 Dibenzosuberones as p38 mitogen-activated protein kinase inhibitors with low ATP competitiveness and outstanding whole blood activity 2013
S Fischer, HK Wentsch, SC Mayer-Wrangowski, M Zimmermann, SM Bauer, K Storch, R Niess, SC Koeberle, C Grütter, FM Boeckler, D Rauh, **S Laufer**
Journal of medicinal chemistry 56 (1), 241-253

368 tert-Butyl-(3R, 4R)-1-(2-cyanoacetyl)-4-methylpiperidin-3-yl (methyl)-carbamate 2013
S Laufer, M Gehringer, M Forster
Acta Crystallographica Section E 69

367 Assessing the target differentiation potential of imidazole-based protein kinase inhibitors 2012
D Dimova, P Iyer, M Vogt, F Totzke, MHG Kubbutat, C Schächtele, **S Laufer**, J Bajorath
Journal of Medicinal Chemistry 55 (24), 11067-11071

366 2-[5-Bromo-1-(3-chlorobenzyl)-2-methyl-1H-indol-3-yl] acetic acid 2012
M Elkady, P Keck, D Schollmeyer, **S Laufer**
Acta Crystallographica Section E: Structure Reports Online 68 (12), o3396-o3396

365 3-(4-Bromophenyl)-1-phenyl-1H-pyrazole-4-carbaldehyde 2012
M Elkady, P Keck, D Schollmeyer, **S Laufer**
Acta Crystallographica Section E: Structure Reports Online 68 (12), o3397-o3397

364 Modified acidic nonsteroidal anti-inflammatory drugs as dual inhibitors of mPGES-1 and 5-LOX 2012
M Elkady, R Nieß, AM Schaible, J Bauer, S Luderer, G Ambrosi, O Werz, **SA Laufer**
Journal of medicinal chemistry 55 (20), 8958-8962

363 A frozen analogue approach to aminopyridinylimidazoles leading to novel and promising p38 MAP kinase inhibitors 2012
R Selig, M Goettert, V Schattel, D Schollmeyer, W Albrecht, **S Laufer**
Journal of Medicinal Chemistry 55 (19), 8429-8439

362 Discovery of Novel Orally Active Anti-Inflammatory *N*-Phenylpyrazolyl-*N*-Glycinyl-Hydrazone Derivatives That Inhibit TNF-α Production 2012
RB Lacerda, LL Da Silva, CKF de Lima, E Miguez, ALP Miranda, **SA Laufer**, EJ Barreiro, CAM Fraga
Public Library of Science 7 (10), e46925

361 1-[(3RS, 4RS)-1-Benzyl-4-methylpiperidin-3-yl]-1, 6-dihydroimidazo [4, 5-d] pyrrolo [2, 3-b] pyridine hemihydrate 2012
E Pfaffenrot, D Schollmeyer, **S Laufer**
Acta Crystallographica Section E: Structure Reports Online 68 (10), o3052-o3052

360 N-[(3RS, 4RS)-1-Benzyl-4-methylpiperidin-3-yl]-5-nitro-1-phenylsulfonyl-1H-pyrrolo [2, 3-b] pyridine-4-amine 2012
E Pfaffenrot, D Schollmeyer, **S Laufer**
Acta Crystallographica Section E: Structure Reports Online 68 (10), o3051-o3051

359 N-[(3RS, 4SR)-1-Benzyl-4-methylpiperidin-3-yl]-1-(4-methylphenylsulfonyl)-5-nitro-1H-pyrrolo [2, 3-b] pyridin-4-amine 2012
E Pfaffenrot, D Schollmeyer, **S Laufer**
Acta Crystallographica Section E: Structure Reports Online 68 (10), o3000-o3000

358 Targeting the hinge glycine flip and the activation loop: novel approach to potent p38α inhibitors 2012
KE Martz, A Dorn, B Baur, V Schattel, MI Goettert, SC Mayer-Wrangowski, D Rauh, **SA Laufer**
Journal of medicinal chemistry 55 (17), 7862-7874

357 On the Reaction of Triphenylphosphane with Thionyl Chloride 2012
HF Klein, A Kuhn, N Kuhn, **S Laufer**, M Ströbele
Zeitschrift für anorganische und allgemeine Chemie 638 (11), 1784-1786

356 4-(4-Fluorophenyl)-3-(pyridin-4-yl)-1-(2, 4, 6-trichlorophenyl)-1H-pyrazol-5-amine 2012
B Abu Thaher, P Koch, D Schollmeyer, **S Laufer**
Acta Crystallographica Section E: Structure Reports Online 68 (9), o2603-o2603

355 PRE-CONDITIONED MAPK ACTIVATED PROTEIN KINASE-2 (MK-2) RESPONSES OF MACROPHAGES TO p38 INHIBITION IN THE ABSENCE OF INTRACELLULAR INHIBITOR, SB203580 2012
N Yousaf, N Malik, M Lees, V Moradi, **S Laufer**, W Albrecht, G Schett, M Burnett, M Seed

INFLAMMATION RESEARCH 61, S24-S24

354 The decrease of cell membrane fluidity by the non-steroidal anti-inflammatory drug Licofelone inhibits epidermal growth factor receptor signalling and triggers apoptosis in HCA … 2012
S Tavolari, A Munarini, G Storci, **S Laufer**, P Chieco, T Guarnieri
Cancer letters 321 (2), 187-194

353 Identification of new γ-hydroxybutenolides that preferentially inhibit the activity of mPGES-1 2012
R De Simone, I Bruno, R Riccio, K Stadler, J Bauer, AM Schaible, **S Laufer**, O Werz
Bioorganic & medicinal chemistry 20 (16), 5012-5016

352 Anti-Inflammatory drug discovery 2012
JI Levin, **S Laufer**
Royal Society of Chemistry

351 Dual Inhibition of Phosphodiesterase-4 and p38 MAP Kinase: A Strategy for Treatment of Chronic Inflammatory Diseases 2012
W ALBRECHT, **S LAUFER**
Anti-Inflammatory Drug Discovery, 137

350 Small-molecule-induced Rho-inhibition: NSAIDs after spinal cord injury 2012
MA Kopp, T Liebscher, A Niedeggen, **S Laufer**, B Brommer, GJ Jungehulsing, SM Strittmatter, U Dirnagl, JM Schwab
Cell and tissue research 349 (1), 119-132

349 Development of a p38δ mitogen activated protein kinase ELISA assay for the quantitative determination of inhibitor activity 2012
M Goettert, N Shaalan, R Graeser, **SA Laufer**
Journal of pharmaceutical and biomedical analysis 66, 349-351

348 Design, synthesis, and biological evaluation of novel disubstituted dibenzosuberones as highly potent and selective inhibitors of p38 mitogen activated protein kinase 2012
SC Koeberle, S Fischer, D Schollmeyer, V Schattel, C Grütter, D Rauh, **SA Laufer**
Journal of medicinal chemistry 55 (12), 5868-5877

347 Abietane diterpenes induce cytotoxic effects in human pancreatic cancer cell line MIA PaCa-2 through different modes of action 2012
M Fronza, E Lamy, S Günther, B Heinzmann, **S Laufer**, I Merfort
Phytochemistry 78, 107-119

346 $\{n\text{BuMg}(OR)\}_2$ and $\{\text{Mg}(OR)_2\}_2$ (R = 2, 4, 6-$t\text{Bu}_3\text{C}_6\text{H}_2$) – Sterically Congested Magnesium Alcoholates 2012
U Flörke, G Henkel, A Kuhn, N Kuhn, **S Laufer**, C Maichle-Mößmer
Zeitschrift für anorganische und allgemeine Chemie 638 (5), 730-732

345 4-[5-Amino-4-(4-fluorophenyl)-3-(pyridin-4-yl)-1H-pyrazol-1-yl] benzonitrile 2012
B Abu Thaher, P Koch, D Schollmeyer, **S Laufer**
Acta Crystallographica Section E: Structure Reports Online 68 (4), o935-o935

344 2-sulfanyl-substituted imidazole derivatives and their use as cytokine inhibitors 2012
M Burnet, **S Laufer**, P Koch
US Patent 8,143,294

343 Inferential NMR/X-ray-Based Structure Determination of a Dibenzo[*a*,*d*]cycloheptenone Inhibitor–p38α MAP Kinase Complex in Solution 2012
VS Honndorf, N Coudevylle, **S Laufer**, S Becker, C Griesinger, M Habeck
Angewandte Chemie International Edition 51 (10), 2359-2362

342 Ethyl 5-amino-3-(pyridin-4-yl)-1-(2, 4, 6-trichlorophenyl)-1H-pyrazole-4-carboxylate dimethyl sulfoxide hemisolvate 2012
BA Thaher, P Koch, D Schollmeyer, **S Laufer**
Acta Crystallographica Section E: Structure Reports Online 68 (Pt 3), o917

341 4-(4-Fluorophenyl)-1-phenyl-3-(pyridin-4-yl)-1H-pyrazol-5-amine 2012
B Abu Thaher, P Koch, D Schollmeyer, **S Laufer**
Acta Crystallographica Section E: Structure Reports Online 68 (3), o632-o632

340 Ethyl 5-amino-3-(pyridin-4-yl)-1-(2, 4, 6-trichlorophenyl)-1H-pyrazole-4-carboxylate dimethyl sulfoxide hemisolvate 2012
B Abu Thaher, P Koch, D Schollmeyer, **S Laufer**
Acta Crystallographica Section E: Structure Reports Online 68 (3), o917-o918

339 4-(4-Fluorophenyl)-1-(4-nitrophenyl)-3-(pyridin-4-yl)-1H-pyrazol-5-amine 2012
B Abu Thaher, P Koch, D Schollmeyer, **S Laufer**
Acta Crystallographica Section E: Structure Reports Online 68 (3), o633-o633

338 Therapeutic Potential of Small Molecules Modulating the Cyclooxygenase–5-Lipoxygenase Pathway 2012
W Albrecht, **S Laufer**
Polypharmacology in Drug Discovery, 383-408

337 Regulation of coronary venular barrier function by blood borne inflammatory mediators and pharmacological tools: insights from novel microvascular wall models 2012
G Juchem, DR Weiss, M Knott, A Senftl, S Förch, T Fischlein, E Kreuzer, B Reichart, **S Laufer**, S Nees

American Journal of Physiology-Heart and Circulatory Physiology 302 (3), H567-H581

336 A Multicomponent Carba-Betti Strategy to Alkylidene Heterodimers–Total Synthesis and Structure–Activity Relationships of Arzanol 2012
A Minassi, L Cicione, A Koeberle, J Bauer, **S Laufer**, O Werz, G Appendino
European journal of organic chemistry 2012 (4), 772-779

335 Skepinone-L is a selective p38 mitogen-activated protein kinase inhibitor 2012
SC Koeberle, J Romir, S Fischer, A Koeberle, V Schattel, W Albrecht, C Grütter, O Werz, D Rauh, T Stehle, **SA Laufer**
Nature chemical biology 8 (2), 141-143

334 Tri-and tetrasubstituted pyrazole derivates: regioisomerism switches activity from p38MAP kinase to important cancer kinases 2012
BA Thaher, M Arnsmann, F Totzke, JE Ehlert, MHG Kubbutat, C Schächtele, MO Zimmermann, P Koch, FM Boeckler, **SA Laufer**
Journal of Medicinal Chemistry 55 (2), 961-965

333 Mechanistic role of p38 MAPK in gastric cancer dissemination in a rodent model peritoneal metastasis 2012
L Graziosi, A Mencarelli, C Santorelli, B Renga, S Cipriani, E Cavazzoni, G Palladino, **S Laufer**, M Burnett, A Donini, S Fiorucci
European journal of pharmacology 674 (2-3), 143-152

332 p38α mitogen-activated protein kinase inhibitors, a patent review (2005–2011) 2011
S Fischer, SC Koeberle, **SA Laufer**
Expert opinion on therapeutic patents 21 (12), 1843-1866

331 The application of Stille cross-coupling reactions with multiple nitrogen containing heterocycles 2011
R Selig, D Schollmeyer, W Albrecht, **S Laufer**
Tetrahedron 67 (47), 9204-9213

330 Polymorphic form of 6-(4-chlorophenyl)-2, 2-dimethyl-7-phenyl-2, 3-dihydro-1h-pyrrolizin-5-ylacetic acid 2011
W Albrecht, T Kammermeier, HG Striegel, P Merckle, **S Laufer**
US Patent 8,034,837

329 1, 4-Dimethyl-2-phenyl-6, 7-dihydro-1H-pyrazolo [4, 3-b] pyridine-3, 5 (2H, 4H)-dione 2011
M Weisser, D Schollmeyer, **S Laufer**
Acta Crystallographica Section E: Structure Reports Online 67 (10), o2586-o2586

328 6-(4-Chlorophenyl)-7-phenyl-2, 3-dihydro-1H-pyrrolizine-5-carbaldehyde 2011
P Keck, D Schollmeyer, **S Laufer**
Acta Crystallographica Section E: Structure Reports Online 67 (9), o2292-o2292

327 6-(4-Methoxyphenyl)-7-phenyl-2, 3-dihydro-1H-pyrrolizine-5-carbaldehyde 2011
P Keck, D Schollmeyer, **S Laufer**
Acta Crystallographica Section E: Structure Reports Online 67 (9), o2417-o2417

326 In vitro cytotoxic activity of abietane diterpenes from Peltodon longipes as well as Salvia miltiorrhiza and Salvia sahendica 2011
M Fronza, R Murillo, S Ślusarczyk, M Adams, M Hamburger, B Heinzmann, **S Laufer**, I Merfort
Bioorganic & medicinal chemistry 19 (16), 4876-4881

325 Four new kaempferol glycosides from the leaves of Brugmansia suaveolens 2011
F Geller, R Murillo, L Steinhauser, B Heinzmann, K Albert, I Merfort, **S Laufer**
Planta Medica 77 (12), PG62

324 Alkoxymagnesium Iodide Complexes 2011
P Haiss, A Kuhn, N Kuhn, C Maichle-Mößmer, **S Laufer**, M Steimann, KP Zeller
European Journal of Inorganic Chemistry 2011 (22), 3284-3287

323 Structural and Conformational Analysis of Proanthocyanidins from *Parapiptadenia rigida* and Their Wound-Healing Properties 2011
CA Schmidt, R Murillo, B Heinzmann, **S Laufer**, V Wray, I Merfort
Journal of natural products 74 (6), 1427-1436

322 Chiral sulfoxides as metabolites of 2-thioimidazole-based p38α mitogen-activated protein kinase inhibitors: Enantioselective synthesis and biological evaluation 2011
S Bühler, M Goettert, D Schollmeyer, W Albrecht, **SA Laufer**
Journal of medicinal chemistry 54 (9), 3283-3297

321 A direct ELISA assay for quantitative determination of the inhibitory potency of small molecules inhibitors for JNK3 2011
M Goettert, S Luik, R Graeser, **SA Laufer**
Journal of pharmaceutical and biomedical analysis 55 (1), 236-240

320 Cell receptor-ligand interaction, signalling, activation and apoptosis: 21. Pregnenolone Sulphate is Similar to Dexamethasone in Supressing the Unfettered Secretion of … 2011
C Ciurtin, Y Majeed, J Naylor, P Sukumar, A English, P Emery, D Beech
Rheumatology 50 (suppl_3), iii50-iii52

319 Modeling and benchmark data set for the inhibition of c-Jun N-terminal kinase-3 2011
V Schattel, G Hinselmann, A Jahn, A Zell, **S Laufer**
Journal of chemical information and modeling 51 (3), 670-679

318 Design, Synthesis and Structure–Activity Relationship of Functionalized Tetrahydro-β-carboline Derivatives as Novel PDE5 Inhibitors 2011
NS Ahmed, BD Gary, HN Tinsley, GA Piazza, **S Laufer**, AH Abadi
Archiv der Pharmazie 344 (3), 149-157

317 Transient exposure of macrophages to P38 map kinase inhibition conditions cell responses through MAPK activated protein kinase-2 regulation 2011
N Malik, M Lees, V Moradi, **S Laufer**, G Schett, M Burnet, M Seed
Annals of the Rheumatic Diseases 70 (Suppl 2), A17-A17

316 3-(2, 4-Difluoroanilino)-9-nitrodibenzo [b, e] oxepin-11 (6H)-one 2011
B Baur, D Schollmeyer, **S Laufer**
Acta Crystallographica Section E: Structure Reports Online 67 (3), o555-o555

315 3-(2, 4-Dimethoxyanilino)-8-methoxydibenz [b, e] oxepin-11 (6H)-one 2011
B Baur, D Schollmeyer, **S Laufer**
Acta Crystallographica Section E: Structure Reports Online 67 (2), o487-o487

314 Regulation of coronary venular barrier function by blood borne inflammatory mediators and pharmacological tools: insights from 2 novel microvascular wall models 3 2011
EK Fischlein, B Reichart, **S Laufer**, S Nees

313 Conformational effects on potency of thioimidazoles and dihydrothiazolines 2011
R Selig, V Schattel, M Goettert, D Schollmeyer, W Albrecht, **S Laufer**
MedChemComm 2 (4), 261-269

312 Catechin Derivatives from *Parapiptadenia rigida* with *in Vitro* Wound-Healing Properties 2010
CA Schmidt, R Murillo, T Bruhn, G Bringmann, M Goettert, B Heinzmann, V Brecht, **SA Laufer**, I Merfort
Journal of natural Products 73 (12), 2035-2041

311 Biological evaluation and structural determinants of p38α mitogen-activated-protein kinase and c-Jun-N-terminal kinase 3 inhibition by flavonoids 2010
M Goettert, V Schattel, P Koch, I Merfort, **S Laufer**
Chembiochem 11 (18), 2579-2588

310 N-(4-Chloropyridin-2-yl)-N-(4-methylphenylsulfonyl) acetamide 2010
S Bühler, D Schollmeyer, W Albrecht, **S Laufer**
Acta Crystallographica Section E: Structure Reports Online 66 (12), o3320-o3320

309 N-(4-Chloropyridin-2-yl)-N-methoxymethyl-4-methylbenzenesulfonamide 2010
S Bühler, D Schollmeyer, W Albrecht, **S Laufer**

Acta Crystallographica Section E: Structure Reports Online 66 (12), o3321-o3321

308 Tri-and tetrasubstituted imidazoles as p38α mitogen-activated protein kinase inhibitors 2010
S Laufer, D Hauser, T Stegmiller, C Bracht, K Ruff, V Schattel, W Albrecht, P Koch
Bioorganic & medicinal chemistry letters 20 (22), 6671-6675

307 Optimization of a nonradioactive immunosorbent assay for p38α mitogen-activated protein kinase activity 2010
M Goettert, R Graeser, **SA Laufer**
Analytical biochemistry 406 (2), 233-234

306 A novel access to arylated and heteroarylated beta-carboline based PDE5 inhibitors 2010
N S Ahmed, B D Gary, G A Piazza, H N Tinsley, **S Laufer**, A H Abadi
Medicinal Chemistry 6 (6), 374-387

305 2-sulfinyl-and 2-sulfonyl-substituted imidazole derivatives and their use as cytokine inhibitors 2010
W Albrecht, C Greim, HG Striegel, K Tollmann, P Merkle, **S Laufer**
US Patent App. 11/817,298

304 Cytotoxic abietane diterpenes from Peltodon longipes and their mode of action 2010
M Fronza, S Günther, R Murillo, E Lamy, B Heinzmann, **S Laufer**, I Merfort
Planta Medica 76 (12), SL_22

303 Catechin derivatives from Parapiptadenia rigida: biological studies and conformational analysis 2010
C Schmidt, M Fronza, R Murillo, V Wray, G Bringmann, T Bruhn, B Heinzmann, **S Laufer**, I Merfort
Planta Medica 76 (12), O_1

302 Rosmarinic acid as the effective compound in Cordia americana 2010
F Geller, C Schmidt, M Goettert, M Fronza, B Heinzmann, O Werz, I Merfort, **S Laufer**
Planta Medica 76 (12), P584

301 One-pot synthesis of 4, 6-diaryl-2-oxo (imino)-1, 2-dihydropyridine-3-carbonitrile; a new scaffold for p38α MAP Kinase Inhibition 2010
AM Serry, S Luik, **S Laufer**, AH Abadi
Journal of Combinatorial Chemistry 12 (4), 559-565

300 Inside Cover: Synthesis and Biological Testing of *N*-Aminoimidazole-Based p38α MAP Kinase Inhibitors (ChemMedChem 7/2010) 2010
C Bracht, DRJ Hauser, V Schattel, W Albrecht, **SA Laufer**
ChemMedChem 5 (7), 966-966

299 Synthesis and Biological Testing of *N*-Aminoimidazole-Based p38α MAP Kinase Inhibitors 2010
C Bracht, DRJ Hauser, V Schattel, W Albrecht, **SA Laufer**
ChemMedChem 5 (7), 1134-1142

298 Differential effects of p38MAP kinase inhibitors on the expression of inflammation-associated genes in primary, interleukin-1β-stimulated human chondrocytes 2010
H Joos, W Albrecht, **S Laufer**, RE Brenner
British journal of pharmacology 160 (5), 1252-1262

297 2-(Bicyclo [2.2. 1] hept-5-en-2-yl)-1H-pyrrolo [2, 3-b] pyridine 2010
R Selig, D Schollmeyer, W Albrecht, **S Laufer**
Acta Crystallographica Section E: Structure Reports Online 66 (7), o1800-o1800

296 N-{2-Methyl-5-[(5-oxo-10, 11-dihydro-5H-dibenzo [a, d] cyclohepten-2-yl) amino] phenyl} benzamide 2010
A Dorn, D Schollmeyer, **SA Laufer**
Acta Crystallographica Section E: Structure Reports Online 66 (7), o1867-o1867

295 Unexpected reaction of 2-alkylsulfanylimidazoles to imidazol-2-ones: Pyridinylimidazol-2-ones as novel potent p38α mitogen-activated protein kinase inhibitors 2010
P Koch, **S Laufer**
Journal of medicinal chemistry 53 (12), 4798-4802

294 Novel p38 MAPK inhibitor ML3403 has potent anti-inflammatory activity in airway smooth muscle 2010
L Munoz, EE Ramsay, M Manetsch, Q Ge, C Peifer, **S Laufer**, AJ Ammit
European journal of pharmacology 635 (1-3), 212-218

293 Fluorescence polarization binding assay to develop inhibitors of inactive p38α mitogen-activated protein kinase 2010
L Munoz, R Selig, YT Yeung, C Peifer, D Hauser, **S Laufer**
Analytical biochemistry 401 (1), 125-133

292 Design, synthesis and SAR of phenylamino-substituted 5, 11-dihydro-dibenzo [a, d] cyclohepten-10-ones and 11H-dibenzo [b, f] oxepin-10-ones as p38 MAP kinase inhibitors 2010
A Dorn, V Schattel, **S Laufer**
Bioorganic & medicinal chemistry letters 20 (10), 3074-3077

291 2-(4-Fluorophenyl)-N-{4-[6-(4-fluorophenyl)-2, 3-dihydroimidazo [2, 1-b][1, 3] thiazol-5-yl] pyridin-2-yl} acetamide 2010
R Selig, D Schollmeyer, W Albrecht, **S Laufer**
Acta Crystallographica Section E: Structure Reports Online 66 (5), o1132-o1132

290 N-[3-(5-Oxo-10, 11-dihydro-5H-dibenzo [a, d] cyclohepten-2-ylamino) phenyl] furan-3-carboxamide 2010
A Dorn, D Schollmeyer, **SA Laufer**
Acta Crystallographica Section E: Structure Reports Online 66 (5), o1100-o1100

289 1-[4-(2-Aminoanilino) phenyl]-2, 2, 2-trifluoroethanone 2010
A Dorn, D Schollmeyer, **SA Laufer**
Acta Crystallographica Section E: Structure Reports Online 66 (5), o1149-o1149

288 Annellated pyrrole compounds for cancer management 2010
S Laufer, T Guarnieri, S Tavolari, V Tomasi, E Palazzini, M Barbanti
US Patent App. 12/375,305

287 Identification of rosmarinic acid as the major active constituent in Cordia americana 2010
F Geller, C Schmidt, M Göttert, M Fronza, V Schattel, B Heinzmann, O Werz, EMM Flores, I Merfort, **S Laufer**
Journal of ethnopharmacology 128 (3), 561-566

286 4-Chloro-7-methoxymethyl-2-phenyl-7H-pyrrolo [2, 3-b] pyridine 2010
R Selig, D Schollmeyer, W Albrecht, **S Laufer**
Acta Crystallographica Section E: Structure Reports Online 66 (4), o822-o822

285 5-(4-Fluorophenyl)-4-(4-pyridyl)-1, 3-oxazol-2-amine 2010
P Koch, D Schollmeyer, **S Laufer**
Acta Crystallographica Section E: Structure Reports Online 66 (4), o917-o917

284 Imidazole compounds having an antiinflammatory effect 2010
W Albrecht, D Hauser, **S Laufer**, HG Striegel, K Tollmann
US Patent App. 12/310,305

283 Pyridinylquinoxalines and pyridinylpyridopyrazines as lead compounds for novel p38α mitogen-activated protein kinase inhibitors 2010
P Koch, H Jahns, V Schattel, M Goettert, **S Laufer**
Journal of medicinal chemistry 53 (3), 1128-1137

282 7-[4-(4-Fluorophenyl)-2-methylsulfanyl-1H-imidazol-5-yl] tetrazolo [1, 5-a] pyridine 2010
R Selig, D Schollmeyer, J Schlosser, W Albrecht, **S Laufer**
Acta Crystallographica Section E: Structure Reports Online 66 (2), o451-o451

281 N-{4-[4-(4-Fluorophenyl)-1-methyl-2-[(R)-methylsulfinyl]-1H-imidazol-5-yl]-2-pyridyl} acetamide dihydrate 2010
S Bühler, D Schollmeyer, D Hauser, W Albrecht, **S Laufer**

Acta Crystallographica Section E: Structure Reports Online 66 (1), o121-o121

280 Different methods for testing potential cyclooxygenase-1 and cyclooxygenase-2 inhibitors 2010
S Laufer, S Luik
Cyclooxygenases: Methods and Protocols, 91-116

279 M1739 Ml3403, a New p38 MAPK Inhibitor, Corrects Immune Dysfunction in Rodent Models of Chronic Inflammatory Disorders 2010
S Fiorucci, **SA Laufer**, A Mencarelli, B Renga, C Booth, GL Tudor, E Distrutti, M Burnet
Gastroenterology 5 (138), S-409

278 3, 4-Diaryl-isoxazoles and-imidazoles as potent dual inhibitors of p38α mitogen activated protein kinase and casein kinase 1δ 2009
C Peifer, M Abadleh, J Bischof, D Hauser, V Schattel, H Hirner, U Knippschild, **S Laufer**
Journal of medicinal chemistry 52 (23), 7618-7630

277 Determination of the wound healing effect of Calendula extracts using the scratch assay with 3T3 fibroblasts 2009
M Fronza, B Heinzmann, M Hamburger, **S Laufer**, I Merfort
Journal of ethnopharmacology 126 (3), 463-467

276 Prediction of breast cancer by profiling of urinary RNA metabolites using Support Vector Machine-based feature selection 2009
C Henneges, D Bullinger, R Fux, N Friese, H Seeger, H Neubauer, **S Laufer**, CH Gleiter, M Schwab, A Zell, B Kammerer
BMC cancer 9, 1-11

275 (2Z)-2-Fluoro-N-{4-[5-(4-fluorophenyl)-2-methylsulfanyl-1H-imidazol-4-yl]-2-pyridyl}-3-phenylacrylamide 2009
R Selig, D Schollmeyer, T Stegmiller, W Albrecht, **S Laufer**
Acta Crystallographica Section E: Structure Reports Online 65 (12), o3284-o3284

274 4-Chloro-1-(4-methylphenylsulfonyl)-1H-pyrrolo [2, 3-b] pyridine 2009
R Selig, D Schollmeyer, W Albrecht, **S Laufer**
Acta Crystallographica Section E: Structure Reports Online 65 (12), o3018-o3018

273 N-{4-[4-(4-Fluorophenyl)-1-(2-methoxyethyl)-2-methylsulfanyl-1H-imidazol-5-yl]-2-pyridyl}-2-methyl-3-phenylpropionamide 2009
K Ziegler, D Schollmeyer, **S Laufer**
Acta Crystallographica Section E: Structure Reports Online 65 (12), o3128-o3128

272 2-(3, 4, 5-Trimethoxyphenyl)-1H-pyrrolo [2, 3-b] pyridine 2009
R Selig, D Schollmeyer, W Albrecht, **S Laufer**

Acta Crystallographica Section E: Structure Reports Online 65 (12), o3097-o3097

271 Accelerated Clearance of *Plasmodium*-infected Erythrocytes in Sickle Cell Trait and Annexin-A7 Deficiency 2009
PA Lang, RS Kasinathan, VB Brand, C Duranton, C Lang, S Koka, E Shumilina, DS Kempe, V Tanneur, A Akel, KS Lang, M Föller, JFJ Kun, PG Kremsner, S Wesselborg, **S Laufer**, CS Clemen, C Herr, AA Noegel, T Wieder, E Gulbins, F Lang, SM Huber
Cellular Physiology and Biochemistry 24 (5-6), 415-428

270 2-Acylaminopyridin-4-ylimidazoles as p38 MAP Kinase Inhibitors: Design, Synthesis, and Biological and Metabolic Evaluations 2009
K Ziegler, DRJ Hauser, A Unger, W Albrecht, **SA Laufer**
ChemMedChem: Chemistry Enabling Drug Discovery 4 (11), 1939-1948

269 4-(4-Fluorophenyl)-1-methoxymethyl-2-phenyl-1H-imidazole 2009
R Selig, D Schollmeyer, W Albrecht, **S Laufer**
Acta Crystallographica Section E: Structure Reports Online 65 (11), o2803-o2803

268 3-(4-Fluorophenyl)-2-(4-pyridyl) pyrido [2, 3-b] pyrazine 2009
P Koch, D Schollmeyer, **S Laufer**
Acta Crystallographica Section E: Structure Reports Online 65 (10), o2546-o2546

267 N-{4-[3-(4-Fluorophenyl) pyrido [2, 3-b] pyrazin-2-yl]-2-pyridyl} isopropylamine 2009
P Koch, D Schollmeyer, **S Laufer**
Acta Crystallographica Section E: Structure Reports Online 65 (10), o2557-o2557

266 2-(4-Fluorophenyl)-3-(4-pyridyl) pyrido [2, 3-b] pyrazine 2009
P Koch, D Schollmeyer, **S Laufer**
Acta Crystallographica Section E: Structure Reports Online 65 (10), o2512-o2512

265 2-[(1-Methyl-1H-pyrrol-2-yl) carbonylmethyl] isoindoline-1, 3-dione 2009
J Schlosser, D Schollmeyer, **S Laufer**, C Peifer
Acta Crystallographica Section E: Structure Reports Online 65 (10), o2375-o2375

264 2-thio-substituted imidazole derivatives and their use in pharmaceutics 2009
S Laufer, HG Striegel, K Tollmann, W Albrecht
US Patent 7,582,660

263 Participation of leukotriene C4 in the regulation of suicidal erythrocyte death 2009
M Foller, H Mahmud, S Gu, K Wang, E Floride, Y Kucherenko, S Luik, **S Laufer**, F Lang
Acta physiologica Polonica 12 (3), 135

262 Arylpyrrolizines as Inhibitors of Microsomal Prostaglandin E_2 Synthase-1 (mPGES-1) or as Dual Inhibitors of mPGES-1 and 5-Lipoxygenase (5-LOX) 2009
AJ Liedtke, PR Keck, F Lehmann, A Koeberle, O Werz, **SA Laufer**
Journal of medicinal chemistry 52 (15), 4968-4972

261 Novel lead structures for p38 MAP kinase via FieldScreen virtual screening 2009
TJ Cheeseright, M Holm, F Lehmann, S Luik, M Gottert, JL Melville, **S Laufer**
Journal of medicinal chemistry 52 (14), 4200-4209

260 3-(4-Fluorophenyl)-6-methoxy-2-(4-pyridyl) quinoxaline 2009
H Jahns, P Koch, D Schollmeyer, **S Laufer**
Acta Crystallographica Section E: Structure Reports Online 65 (7), o1626-o1626

259 Protective effects of licofelone, a 5-lipoxygenase and cyclo-oxygenase inhibitor, versus naproxen on cartilage loss in knee osteoarthritis: a first multicentre clinical trial … 2009
JP Raynauld, J Martel-Pelletier, P Bias, **S Laufer**, B Haraoui, D Choquette, AD Beaulieu, F Abram, M Dorais, E Vignon, JP Pelletier, Canadian Licofelone Study Group
Annals of the rheumatic diseases 68 (6), 938-947

258 4-[3-(4-Fluorophenyl) quinoxalin-2-yl]-N-isopropylpyridin-2-amine 2009
P Koch, D Schollmeyer, **S Laufer**
Acta Crystallographica Section E: Structure Reports Online 65 (6), o1344-o1344

257 1-[2-(Benzylamino)-4-pyridyl]-2-(4-fluorophenyl) ethane-1, 2-dione 2009
H Jahns, P Koch, D Schollmeyer, **S Laufer**
Acta Crystallographica Section E: Structure Reports Online 65 (6), o1451-o1451

256 Colocalization of the VEGF-R2 and the common IL-3/GM-CSF receptor beta chain to lipid rafts leads to enhanced p38 activation 2009
E Saulle, R Riccioni, S Coppola, I Parolini, D Diverio, V Riti, G Mariani, **S Laufer**, M Sargiacomo, U Testa
British journal of haematology 145 (3), 399-411

255 Successful structure-based design of recent p38 MAP kinase inhibitors 2009
SC Karcher, **SA Laufer**
Current Topics in Medicinal Chemistry 9 (7), 655-676

254 Influence of p38MAPK inhibition on IL-1β-stimulated human chondrocytes: A microarray approach 2009
H Joos, W Albrecht, **S Laufer**, RE Brenner
International journal of molecular medicine 23 (5), 685-693

253 Role of the hydrogen bonding heteroatom− Lys53 interaction between the p38α mitogen-activated protein (MAP) kinase and pyridinyl-substituted 5-membered heterocyclic ring inhibitors 2009
BA Thaher, P Koch, V Schattel, **S Laufer**
Journal of medicinal chemistry 52 (8), 2613-2617

252 Dibenzocycloheptane compounds and pharmaceuticals containing these compounds 2009
S Laufer, W Albrecht, C Greim, HG Striegel, K Tollmann
US Patent App. 11/914,078

251 Biological studies on Brazilian plants used in wound healing 2009
C Schmidt, M Fronza, M Goettert, F Geller, S Luik, EMM Flores, CF Bittencourt, GD Zanetti, BM Heinzmann, **S Laufer**, I Merfort
Journal of ethnopharmacology 122 (3), 523-532

250 Method for subgroup analysis in subjects having or being suspected of having inflammatory disease, use of anti-p38MAPK antibodies, kits and their use 2009
G Schett, W Albrecht, **S Laufer**
US Patent App. 11/871,565

249 Rapid and easy access to indoles via microwave-assisted Hemetsberger–Knittel synthesis 2009
F Lehmann, M Holm, **S Laufer**
Tetrahedron Letters 50 (15), 1708-1709

248 Design, synthesis and characterization of N9/N7-substituted 6-aminopurines as VEGF-R and EGF-R inhibitors 2009
C Peifer, S Bühler, D Hauser, K Kinkel, F Totzke, C Schächtele, **S Laufer**
European journal of medicinal chemistry 44 (4), 1788-1793

247 Aza-analogue dibenzepinone scaffolds as p38 mitogen-activated protein kinase inhibitors: design, synthesis, and biological data of inhibitors with improved physicochemical … 2009
SC Karcher, **SA Laufer**
Journal of medicinal chemistry 52 (6), 1778-1782

246 Targeting Proteinkinases: The Selectivity Problem 2009
S LAUFER, G AHRENS, S KARCHER, R NIESS, J HERING
Scientia Pharmaceutica 77 (5), 165

245 4-[2-(4-Fluorophenyl)-1H-pyrrol-3-yl] pyridine 2009
B Abu Thaher, P Koch, D Schollmeyer, **S Laufer**
Acta Crystallographica Section E: Structure Reports Online 65 (3), o457-o457

244 4-[2-(4-Fluorophenyl) furan-3-yl] pyridine 2009
B Abu Thaher, P Koch, D Schollmeyer, **S Laufer**
Acta Crystallographica Section E: Structure Reports Online 65 (3), o458-o458

243 Investigations of SCIO-469-like compounds for the inhibition of p38 MAP kinase 2009
S Laufer, F Lehmann
Bioorganic & Medicinal Chemistry Letters 19 (5), 1461-1464

242 4-[5-(4-Fluorophenyl)-1H-imidazol-4-yl] pyridine 2009
P Koch, D Schollmeyer, **S Laufer**
Acta Crystallographica Section E: Structure Reports Online 65 (3), o573-o573

241 Analysis of the precision and sensitivity to change of different approaches to assess cartilage loss by quantitative MRI in a longitudinal multicentre clinical trial in … 2008
JP Raynauld, J Martel-Pelletier, F Abram, M Dorais, B Haraoui, D Choquette, P Bias, KH Emmert, **S Laufer**, JP Pelletier
Arthritis research & therapy 10 (6), 1-8

240 tert-Butyl N-benzyl-N-(4-methyl-2-pyridyl) carbamate 2008
P Koch, D Schollmeyer, **S Laufer**
Acta Crystallographica Section E: Structure Reports Online 64 (11), o2222-o2222

239 tert-Butyl N-(4-methyl-2-pyridyl) carbamate 2008
P Koch, D Schollmeyer, **S Laufer**
Acta Crystallographica Section E: Structure Reports Online 64 (11), o2216-o2216

238 tert-Butyl N-benzyl-N-[4-(4-fluorobenzoylmethyl)-2-pyridyl] carbamate 2008
P Koch, D Schollmeyer, **S Laufer**
Acta Crystallographica Section E: Structure Reports Online 64 (11), o2221-o2221

237 Związki pirolizynowe, środek farmaceutyczny i zastosowanie związków pirolizynowych 2008
S Laufer, K Neher, HG Striegel

236 2-thio-substituted imidazole derivatives and their use in pharmaceutics 2008
S Laufer, HG Striegel, W Albrecht, K Tollmann
US Patent 7,442,713

235 Identification of urinary modified nucleosides and ribosylated metabolites in humans via combined ESI-FTICR MS and ESI-IT MS analysis 2008
D Bullinger, R Fux, G Nicholson, S Plontke, C Belka, **S Laufer**, CH Gleiter, B Kammerer
Journal of the American Society for Mass Spectrometry 19, 1500-1513

234 Targeting the ribose and phosphate binding site of p38 mitogen-activated protein (MAP) kinase: Synthesis and biological testing of 2-alkylsulfanyl-, 4 (5)-aryl-, 5 (4 … 2008
P Koch, C Bäuerlein, H Jank, **S Laufer**

Journal of medicinal chemistry 51 (18), 5630-5640

233 Medizinische Chemie und molekulare Hemmmechanismen der Tyrosinkinase-Inhibitoren. Schwerpunkt pharmazeutischer Forschung 2008
M Holm, F Lehmann, **S Laufer**
Pharmazie in unserer Zeit 37 (5), 382-392

232 Metabolic signature of breast cancer cell line MCF–7: Profiling of modified nucleosides via LC-IT MS coupling 2008
H Neubauer, D Bullinger, T Fehm, **S Laufer**, C Gleiter, B Kammerer
Geburtshilfe und Frauenheilkunde 68 (S 01), PO_Onko_01_19

231 Metabolische Signatur der Mammakarzinomzell-Linie MCF-7: Profiling modifizierter Nukleoside mittels LC-IT MS 2008
H Neubauer, D Bullinger, T Fehm, **S Laufer**, C Gleiter, B Kammerer
Senologie-Zeitschrift für Mammadiagnostik und-therapie 5 (03), A103

230 Licofelone suppresses prostaglandin E2 formation by interference with the inducible microsomal prostaglandin E2 synthase-1 2008
A Koeberle, U Siemoneit, U Bühring, H Northoff, **S Laufer**, W Albrecht, O Werz
Journal of Pharmacology and Experimental Therapeutics 326 (3), 975-982

229 Human whole blood assay for rapid and routine testing of non-steroidal anti-inflammatory drugs (NSAIDs) on cyclo-oxygenase-2 activity 2008
S Laufer, C Greim, S Luik, SS Ayoub, F Dehner
Inflammopharmacology 16, 155-161

228 Design, synthesis, and biological evaluation of novel Tri-and tetrasubstituted imidazoles as highly potent and specific ATP-mimetic inhibitors of p38 MAP kinase: Focus on … 2008
SA Laufer, DRJ Hauser, DM Domeyer, K Kinkel, AJ Liedtke
Journal of medicinal chemistry 51 (14), 4122-4149

227 Design, Synthesis, and Biological Evaluation of Novel 3-Aryl-4-(1*H*-indole-3yl)-1,5-dihydro-2*H*-pyrrole-2-ones as Vascular Endothelial Growth Factor Receptor … 2008
C Peifer, R Selig, K Kinkel, D Ott, F Totzke, C Schächtele, R Heidenreich, M Röcken, D Schollmeyer, **S Laufer**
Journal of medicinal chemistry 51 (13), 3814-3824

226 Methyl 4-[5-(4-fluorophenyl)-4-(pyridin-4-yl)-1H-imidazol-2-ylsulfanyl] butanoate 2008
P Koch, C Bäuerlein, D Schollmeyer, **S Laufer**
Acta Crystallographica Section E: Structure Reports Online 64 (7), o1183-o1184

225 The scratch assay: A suitable in vitro tool for studying wound healing effects 2008
M Fronza, F Geller, C Bittencourt, E Flores, B Heinzmann, **S Laufer**, I Merfort

Planta Medica 74 (09), PD4

224 Bioinformatical evaluation of modified nucleosides as biomedical markers in diagnosis of breast cancer 2008
D Bullinger, H Fröhlich, F Klaus, H Neubauer, A Frickenschmidt, C Henneges, A Zell, **S Laufer**, CH Gleiter, H Liebich, B Kammerer
Analytica Chimica Acta 618 (1), 29-34

223 In vitro metabolism of 2-[6-(4-chlorophenyl)-2, 2-dimethyl-7-phenyl-2, 3-dihydro-1H-pyrrolizin-5-yl] acetic acid (licofelone, ML3000), an inhibitor of cyclooxygenase-1 and-2 … 2008
W Albrecht, A Unger, AK Nussler, **S Laufer**
Drug metabolism and disposition 36 (5), 894-903

222 Dynamics in the p38α MAP Kinase–SB203580 Complex Observed by Liquid-State NMR Spectroscopy 2008
VS Honndorf, N Coudevylle, **S Laufer**, S Becker, C Griesinger
Angewandte Chemie 120 (19), 3604-3607

221 Isoxazolone based inhibitors of p38 MAP kinases 2008
SA Laufer, S Margutti
Journal of medicinal chemistry 51 (8), 2580-2584

220 Inhibition of GSK3 differentially modulates NF-κB, CREB, AP-1 and β-catenin signaling in hepatocytes, but fails to promote TNF-α-induced apoptosis 2008
F Götschel, C Kern, S Lang, T Sparna, C Markmann, J Schwager, S McNelly, F von Weizsäcker, **S Laufer**, A Hecht, I Merfort
Experimental cell research 314 (6), 1351-1366

219 3-(2-Fluorophenyl)-6-(phenoxymethyl)-1, 2, 4-triazolo [3, 4-b][1, 3, 4] thiadiazole 2008
M Holm, D Schollmeyer, **S Laufer**
Acta Crystallographica Section E: Structure Reports Online 64 (4), o700-o700

218 6-Amino-1-benzyl-4-(4-chlorophenyl)-3-(4-pyridyl)-1, 4-dihydropyrano [2, 3-c] pyrazole-5-carbonitrile 2008
F Lehmann, D Schollmeyer, **S Laufer**
Acta Crystallographica Section E: Structure Reports Online 64 (4), o701-o701

217 The dual inhibitor of lipoxygenase and cyclooxygenase ML3000 decreases the expression of CXCR3 ligands 2008
C Ospelt, M Kurowska-Stolarska, M Neidhart, BA Michel, RE Gay, **S Laufer**, S Gay
Annals of the rheumatic diseases 67 (4), 524-529

216 Protizápalové oxo-a hydroxyderiváty pyrolizínov a ich použitie vo farmácii 2008
S Laufer, K Tollmann, HG Striegel

215 A Software Solution Automatically Assigns Formulae for Construction of Fragmentation Pathways Accelerating Drug Elucidation with ESI-TOF. 2008
G Zurek, I Krebs, S Goetz, H Scheible, **S Laufer**, B Kammerer, W Albrecht
LC-GC Europe

214 IL-1β regulates FHL2 and other cytoskeleton-related genes in human chondrocytes 2008
H Joos, W Albrecht, **S Laufer**, H Reichel, RE Brenner
Molecular medicine 14, 150-159

213 Implications for selectivity of 3, 4-diarylquinolinones as p38αMAP kinase inhibitors 2008
C Peifer, R Urich, V Schattel, M Abadleh, M Röttig, O Kohlbacher, **S Laufer**
Bioorganic & medicinal chemistry letters 18 (4), 1431-1435

212 In vitro metabolism of Licofelone (ML3000), an Inhibitor of Cyclooxygenases-1 and-2 and 5-Lipoxygenase 2008
W Albrecht, A Unger, AK Nuessler, **S Laufer**
Drug Metabolism and Disposition

211 Licofelone, a dual COX/5-LOX inhibitor, induces apoptosis in HCA-7 colon cancer cells through the mitochondrial pathway independently from its ability to affect the arachidonic … 2008
S Tavolari, M Bonafe, M Marini, C Ferreri, G Bartolini, E Brighenti, S Manara, V Tomasi, **S Laufer**, T Guarnieri
Carcinogenesis 29 (2), 371-380

210 4-(4-Fluorophenyl)-2-methyl-3-(1-oxy-4-pyridyl) isoxazol-5 (2H)-one 2008
S Margutti, D Schollmeyer, **S Laufer**
Acta Crystallographica Section E: Structure Reports Online 64 (2), o504-o504

209 4-[4-(4-Fluorophenyl)-2-methyl-5-oxo-2, 5-dihydroisoxazol-3-yl]-1-methylpyridinium iodide–4-[3-(4-fluorophenyl)-2-methyl-5-oxo-2, 5-dihydroisoxazol-4-yl]-1-methylpyridinium … 2008
S Margutti, D Schollmeyer, **S Laufer**
Acta Crystallographica Section E: Structure Reports Online 64 (1), o298-o299

208 Inhibition of GSK3 differentially modulates NF-? B, CREB, AP-1 and?-catenin signaling in hepatocytes, but fails to promote TNF-?-induced apoptosis 2008
F G tschel, C Kern, S Lang, T Sparna, C Markmann, J Schwager, S McNelly, F von Weizsäcker, **S Laufer**, A Hecht, I Merfort
Experimental Cell Research 314 (6), 1351-1366

207 Metabonomics in cancer diagnosis: mass spectrometry-based profiling of urinary nucleosides from breast cancer patients 2008

A Frickenschmidt, H Fröhlich, D Bullinger, A Zell, **S Laufer**, CH Gleiter, H Liebich, B Kammerer
Biomarkers 13 (4), 435-449

206 Medical chemistry and molecular mechanisms of tyrosine kinase inhibitors. The viewpoint of pharmaceutical research 2008
M Holm, F Lehmann, **S Laufer**
Pharmazie in unserer Zeit 37 (5), 382-392

205 A Convenient Synthesis of 1-(4-Fluorophenyl)-2-(4-pyridyl) cyclopentene from Cyclopentanone 2008
BA Thaher, P Koch, V Del Amo, P Knochel, **S Laufer**
Synthesis 2008 (02), 225-228

204 Inhibitory effect of inflammatory mediator by Orostachys japonicus in mouse peritoneal macrophages 2008
P Koch, JH Guse, M Burnet, **S Laufer**
INFLAMMATION RESEARCH 57, S99-S99

203 Three-component combinatorial synthesis of novel dihydropyrano [2, 3-c] pyrazoles 2008
F Lehmann, M Holm, **S Laufer**
Journal of Combinatorial Chemistry 10 (3), 364-367

202 4-aryl-5-heteroaryl-2-thio-substituted imidazoles: Approach to p38 MAP kinase inhibitor prodrugs 2008
P Koch, JH Guse, M Burnet, **S Laufer**
INFLAMMATION RESEARCH 57, S99-S100

201 Regiospecific and highly flexible synthesis of 1, 4, 5-trisubstituted 2-sulfanylimidazoles from structurally diverse ethanone precursors 2008
SA Laufer, DRJ Hauser, AJ Liedtke
Synthesis 2008 (02), 253-266

200 Preconditioning lymphocytes with p38 MAPK inhibitors, and not accessory cells, prevents Con-A-induced lymphocyte responses 2008
V Moradi, E Johnson, L Dugo, V Holan, M Burnet, **S Laufer**, M Seed
INFLAMMATION RESEARCH 57, S106

199 Towards the improvement of the synthesis of novel 4 (5)-aryl-5 (4)-heteroaryl-2-thio-substituted imidazoles and their p38 MAP kinase inhibitory activity 2008
S Laufer, P Koch
Organic & Biomolecular Chemistry 6 (3), 437-439

198 Metabolic signature of breast cancer cell line MCF-7: profiling of modified nucleosides via LC-IT MS coupling 2007
D Bullinger, H Neubauer, T Fehm, **S Laufer**, CH Gleiter, B Kammerer
BMC biochemistry 8, 1-14

197 2-(6-Amino-7H-purin-7-yl)-1-phenylethanone 2007
S Buehler, D Schollmeyer, D Hauser, **S Laufer**, C Peifer
Acta Crystallographica Section E: Structure Reports Online 63 (12), o4646-o4647

196 2-(6-Methoxy-7H-purin-7-yl)-1-phenylethanone monohydrate 2007
S Buehler, D Schollmeyer, D Hauser, **S Laufer**, C Peifer
Acta Crystallographica Section E: Structure Reports Online 63 (10), o4154-o4155

195 Are MAP kinases drug targets? Yes, but difficult ones 2007
S Margutti, **SA Laufer**
ChemMedChem: Chemistry Enabling Drug Discovery 2 (8), 1116-1140

194 2-thio-substituted imidazole derivatives and the use thereof in the pharmaceutical industry 2007
S Laufer, D Kotschenreuther, P Merckle, K Tollmann, HG Striegel
US Patent 7,253,191

193 2-(4-Fluorophenyl)-1-(4-pyridyl) cyclopentan-1-ol 2007
B Abu Thaher, D Schollmeyer, **S Laufer**
Acta Crystallographica Section E: Structure Reports Online 63 (8), o3531-o3531

192 Chondroprotective effects of licofelone, a fop00728 b-llpvxyutnase and cyclooxygenase inhibitor, vis-a-vis naproxen in knee osteoarthritis (OA): A two-year study using … 2007
JP Pelletier, JR Raynauld, P Bias, **S Laufer**, B Haraoui, D Choquette, F Abram, E Vignon, J Martel-Pelletier
ANNALS OF THE RHEUMATIC DISEASES 66, 59-59

191 Isoxazoles as p38 MAPk inhibitors. interaction with atp binding site 2007
S Margutti, **S Laufer**
INFLAMMATION RESEARCH 56, S446-S447

190 Synthesis and structure-activity relationships of [1, 2, 4] triazolo [3, 4-B] [1, 3, 4] thiadiazole derivates as novel p38 mapk-inhibitors 2007
M Holm, **S Laufer**
INFLAMMATION RESEARCH 56, S446-S446

189 Dendritic cell: T cell interactions and p38 mapkinase inhibition 2007
M Seed, E Johnson, M Burnet, V Holan, **S Laufer**
INFLAMMATION RESEARCH 56, S433-S434

188 4-Aryl-5-heteroaryl-2-thio-imidazoles: warhead for a macrocycle-based drug targeting 2007
P Koch, **S Laufer**
INFLAMMATION RESEARCH 56, S446-S446

187 p38 map kinase inhibitor prodrugs tropic for macrophages and neutrophils exert enhanced anti-inflammatory activity in IBD and collagen induced arthritis models 2007
JH Guse, M Burnet, S Luik, **S Laufer**, M Seed, V Holan, S Fiorucci
INFLAMMATION RESEARCH 56, S434-S434

186 Validation of a diluted whole blood assay to evaluate cytokine release inhibitors 2007
S Luik, **S Laufer**
INFLAMMATION RESEARCH 56, S446-S446

185 Pharmacokinetics of ML3403 ({4-[5-(4-fluorophenyl)-2-methylsulfanyl-3H-imidazol-4-yl]-pyridin-2-yl}-(1-phenylethyl)-amine), a 4-pyridinylimidazole-type p38 mitogen-activated … 2007
B Kammerer, H Scheible, W Albrecht, CH Gleiter, **S Laufer**
Drug metabolism and disposition 35 (6), 875-883

184 Synthesis, biological testing, and binding mode prediction of 6, 9-diarylpurin-8-ones as p38 MAP kinase inhibitors 2007
DRJ Hauser, T Scior, DM Domeyer, B Kammerer, **SA Laufer**
Journal of medicinal chemistry 50 (9), 2060-2066

183 (2aRS, 3RS, 4aSR, 6aRS, 6bSR)-3-Hydroxy-2a, 3, 4a, 6, 6a, 6b-hexahydro-1, 4-dioxacyclopenta [cd] pentalen-2 (5H)-one 2007
C Peifer, D Schollmeyer, M Tschertsche, **S Laufer**
Acta Crystallographica Section E: Structure Reports Online 63 (5), o2249-o2251

182 3-(4-Fluorophenyl)-1-methyl-4-(4-pyridyl) quinolin-2 (1H)-one 2007
C Peifer, D Schollmeyer, K Kinkel, **S Laufer**
Acta Crystallographica Section E: Structure Reports Online 63 (5), o2457-o2459

181 2, 2-Dimethyl-N-[3-(3, 4, 5-trimethoxybenzoyl) pyridin-4-yl] propanamide 2007
K Kinkel, **S Laufer**, D Schollmeyer, C Peifer
Acta Crystallographica Section E: Structure Reports Online 63 (4), o1887-o1889

180 rac-(3E, 3aR, 6aR)-3-(Hydroxymethylene)-3, 3a, 6, 6a-tetrahydro-2H-cyclopenta [b] furan-2-one 2007
C Peifer, D Schollmeyer, M Tschertsche, **S Laufer**
Acta Crystallographica Section E: Structure Reports Online 63 (4), o1551-o1553

179 From five-to six-membered rings: 3, 4-diarylquinolinone as lead for novel p38MAP kinase inhibitors 2007
C Peifer, K Kinkel, M Abadleh, D Schollmeyer, **S Laufer**
Journal of medicinal chemistry 50 (6), 1213-1221

178 Pharmacokinetics of ML3403, a 4-pyridinylimidazole-type p38 MAP kinase inhibitor 2007
B Kammerer, H Scheible, W Albrecht, C Gleiter, **S Laufer**
Drug Metabolism and Disposition

177 N-{(Z)-2-[1-(Triisopropylsilyl)-1H-indol-3-yl]-2-(triisopropylsilyloxy) vinyl}-2-(3, 4, 5-trimethoxyphenyl) acetamide 2007
C Peifer, R Selig, D Schollmeyer, **S Laufer**
Acta Crystallographica Section E: Structure Reports Online 63 (3), o1266-o1268

176 (1aR, 2aS, 5aS, 5bS)-Perhydro-4H-oxireno [3, 4] cyclopenta [1, 2-b] furan-4-one 2007
C Peifer, M Tschertsche, D Schollmeyer, **S Laufer**
Acta Crystallographica Section E: Structure Reports Online 63 (3), o1359-o1360

175 *In vitro* metabolite identification of ML3403, a 4-pyridinylimidazole-type p38 MAP kinase inhibitor by LC-Qq-TOF-MS and LC-SPE-cryo-NMR/MS 2007
B Kammerer, H Scheible, G Zurek, M Godejohann, KP Zeller, CH Gleiter, W Albrecht, **S Laufer**
Xenobiotica 37 (3), 280-297

174 Ethyl (2, 3-dihydro-1H, 1′ H-2, 3′-biindol-1-yl) glyoxylate 2007
C Peifer, D Ott, D Schollmeyer, **S Laufer**
Acta Crystallographica Section E: Structure Reports Online 63 (3), o1415-o1417

173 4-[5-(4-Fluorophenyl)-3-isopropylisoxazol-4-yl] pyridin-2 (1H)-one 2007
M Abadleh, C Peifer, K Kinkel, D Schollmeyer, **S Laufer**
Acta Crystallographica Section E: Structure Reports Online 63 (3), o1423-o1425

172 Macrolide conjugates of pyrrolizine and indolizine compounds as inhibitors of 5-lipooxygenase and cyclooxygenase 2007
S Laufer, W Albrecht, M Burnet, HJ Gutke

171 Design, Synthesis, and Biological Evaluation of Phenylamino-Substituted 6,11-Dihydro-dibenzo[*b*,*e*]oxepin-11-ones and Dibenzo[*a*,*d*]cycloheptan-5-ones … 2006
SA Laufer, GM Ahrens, SC Karcher, JS Hering, R Niess
Journal of medicinal chemistry 49 (26), 7912-7915

170 Profile and Molecular Modeling of 3-(Indole-3-yl)-4-(3,4,5-trimethoxyphenyl)-1*H*-pyrrole-2,5dione (**1**) as a Highly Selective VEGF-R2/3 Inhibitor 2006
C Peifer, A Krasowski, N Hämmerle, O Kohlbacher, G Dannhardt, F Trotzke, C Schächtele, **S Laufer**
Journal of medicinal chemistry 49 (25), 7549-7553

169 Licofelone, a 5-lipoxygenase and cyclooxygenase inhibitor, reduces the progression of knee osteoarthritis (OA): A double blind, multicenter 2-year study using quantitative MRI. 2006
JP Pelletier, JP Raynauld, P Bias, **S Laufer**, B Haraoui, D Choquette, F Abram, E Vignon, J Martel-Pelletier
ARTHRITIS AND RHEUMATISM 54 (12), 4119-4119

168 Stimulation of suicidal erythrocyte death by lipoxygenase inhibitor Bay-Y5884 2006
E Shumilina, V Kiedaisch, A Akkel, P Lang, T Hermle, D Kempe, S Huber, T Wieder, **S Laufer**, F Lang
Cellular Physiology and Biochemistry 18 (4-5), 233-242

167 Dibenzocycloheptanverbindungen und pharmazeutische mittel, welche diese verbindungen enthalten 2006
S Laufer, W Albrecht, C Greim, HG Striegel, K Tollmann

166 3, 4-Bis (4-fluorophenyl)-1, 2, 5-oxadiazole 2-oxide 2006
C Peifer, M Abadleh, D Schollmeyer, **S Laufer**
Acta Crystallographica Section E: Structure Reports Online 62 (11), o4827-o4828

165 (4R)-4-Hydroxy-1-[(2S)-2-hydroxydodecyl]-l-proline monohydrate 2006
C Peifer, O Werz, D Poeckel, D Schollmeyer, **S Laufer**
Acta Crystallographica Section E: Structure Reports Online 62 (11), o5138-o5140

164 A concise and optimized four-step approach toward 2-(aryl-) alkylsulfanyl-, 4 (5)-aryl-, 5 (4)-heteroaryl-substituted imidazoles using alkyl-or arylalkyl thiocyanates 2006
SA Laufer, AJ Liedtke
Tetrahedron letters 47 (40), 7199-7203

163 Inhibition of P38 kinase prevents T-cell responsiveness to allogenic dendritic cells 2006
E Johnson, **S Laufer**, V Holan, M Burnet, MP Seed
INFLAMMATION RESEARCH 55, S118-S118

162 Development and optimization of a non-radioactive JNK3 assay 2006
C Peifer, S Luik, S Thuma, Y Herweh, **S Laufer**
Combinatorial Chemistry & High Throughput Screening 9 (8), 613-618

161 4-[5-(4-Fluorophenyl)-3-isopropylisoxazol-4-yl] pyridine 2006
C Peifer, M Abadleh, D Schollmeyer, **S Laufer**
Acta Crystallographica Section E: Structure Reports Online 62 (9), o3647-o3649

160 4-[3-(4-Fluorophenyl)-5-isopropylisoxazol-4-yl] pyridine 2006
C Peifer, M Abadleh, D Schollmeyer, **S Laufer**
Acta Crystallographica Section E: Structure Reports Online 62 (9), o3707-o3709

159 Development of a Microsphere-Based p38α MAP Kinase No-Wash Assay 2006
S Laufer, S Linsenmaier
SLAS Discovery 11 (5), 528-536

158 Method for the production of 6-(4-chlorophenyl)-2, 2-dimethyl-7-phenyl-2, 3-dihydro-1h-pyrrolizin-5-ylacetic acid 2006
G Dannhardt, T Kammermeier, P Merckle, HG Striegel, **S Laufer**
US Patent 7,078,535

157 4-(4-Fluorophenyl)-3-(4-pyridyl) quinolin-2 (1H)-one 2006
C Peifer, D Schollmeyer, R Selig, **S Laufer**
Acta Crystallographica Section E: Structure Reports Online 62 (7), o2648-o2650

156 Substituted isoxazole derivatives and their use in pharmaceutics 2006
S Laufer, HG Striegel, W Albrecht, K Tollmann
US Patent App. 10/524,839

155 3-(4-Fluorophenyl)-4-(4-pyridyl) quinolin-2 (1H)-one 2006
C Peifer, D Schollmeyer, S Laudage, **S Laufer**
Acta Crystallographica Section E: Structure Reports Online 62 (6), o2475-o2477

154 Licofelone reduces progression of structural changes in a canine model of osteoarthritis under curative conditions: effect on protease expression and activity. 2006
M Moreau, C Boileau, J Martel-Pelletier, J Brunet, **S Laufer**, JP Pelletier
The Journal of Rheumatology 33 (6), 1176-1183

153 Sesquiterpene lactones as inhibitors of IL-8 expression in HeLa cells 2006
MT Lindenmeyer, A Hrenn, C Kern, V Castro, R Murillo, S Müller, **S Laufer**, J Schulte-Mönting, B Siedle, I Merfort
Bioorganic & Medicinal Chemistry 14 (8), 2487-2497

152 Discovery and development of LICOFELONE (ML3000) 2006
S Laufer
PROSTAGLANDINS & OTHER LIPID MEDIATORS 79 (1-2), 161-161

151 Substituted isoxazoles as potent inhibitors of p38 MAP kinase 2006
SA Laufer, S Margutti, MD Fritz
ChemMedChem: Chemistry Enabling Drug Discovery 1 (2), 197-207

150 Identification of urinary nucleosides by ESI-TOF-MS 2006
M Pelzing, T Zey, G Zurek, D Bullinger, A Frickenschmidt, **S Laufer**, B Kammerer
LC GC NORTH AMERICA 24 (2), 14

149 Quantitative determination of piritramide in human plasma and urine by off-and on-line solid-phase extraction liquid chromatography coupled to tandem mass spectrometry 2006

R Kahlich, CH Gleiter, **S Laufer**, B Kammerer
Rapid Communications in Mass Spectrometry: An International Journal Devoted …

148 High anti-inflammatory activity of harpagoside-enriched extracts obtained from solvent-modified super-and subcritical carbon dioxide extractions of the roots of Harpagophytum … 2006
M Günther, **S Laufer**, PC Schmidt
Phytochemical Analysis: An International Journal of Plant Chemical and …

147 A novel naturally occurring tripyrrole with potential nuclease and anti-tumour properties pp 2480–2486 2006
M Subramanian, R Chander, S Chattopadhyay, MT Lindenmeyer, A Hrenn, C Kern, V Castro, R Murillo, S Müller, **S Laufer**, J Schulte-Mönting, B Siedle, I Merfort
Bioorganic & Medicinal Chemistry 14 (8)

146 Small molecular anti-cytokine agents 2006
G Wagner, **S Laufer**
Medicinal research reviews 26 (1), 1-62

145 Small Molecule Inhibitors of p38 MAP Kinase 2006
C Peifer, G Wagner, **S Laufer**
Current Topics in Medicinal Chemistry 6, 000-000

144 Complete Characterization of ML 3403 Metabolites from Liver Microsomes using ESI-Qq-TOF-MS and LC-SPE-cryo NMR/MS 2006
H Scheible, **S Laufer**, W Albrecht, CH Gleiter, G Zurek, M Spraul, M Godejohann, B Kammerer
54 th ASMS Conference Proceedings

143 New approaches to the treatment of inflammatory disorders small molecule inhibitors of p38 MAP kinase 2006
C Peifer, G Wagner, **S Laufer**
Current topics in medicinal chemistry 6 (2), 113-149

142 The effect of single-dose naproxen on eicosanoid formation in human gastroduodenal mucosa 2006
G Treiber, T Wex, A Link, M Vieth, **S Laufer**, P Malfertheiner
Alimentary pharmacology & therapeutics 23 (1), 155-167

141 Identification of urinary nucleosides by ESI-TOF-MS 2005
D Bullinger, A Frickenschmidt, M Pelzing, G Zurek, **S Laufer**, T Zey, B Kammerer
Advanstar Communications Inc.

140 Stereospecific pharmacokinetic characterisation of phenprocoumon metabolites, and mass-spectrometric identification of two novel metabolites in human plasma and liver microsomes 2005
B Kammerer, R Kahlich, M Ufer, A Schenkel, **S Laufer,** CH Gleiter

Analytical and bioanalytical chemistry 383, 909-917

139 Are vanadium compounds drugable? Structures and effects of antidiabetic vanadium compounds: a critical review 2005
T Scior, A Guevara-García, P Bernard, QT Do, D Domeyer, **S Laufer**
Mini reviews in medicinal chemistry 5 (11), 995-1008

138 The protective effect of licofelone on experimental osteoarthritis is correlated with the downregulation of gene expression and protein synthesis of several major cartilage … 2005
JP Pelletier, C Boileau, M Boily, J Brunet, F Mineau, C Geng, P Reboul, **S Laufer**, D Lajeunesse, M Martel-Pelletier
Arthritis research & therapy 7 (5), 1-12

137 Fused pyrrole compounds, pharmaceutical agents containing the same, and the use thereof 2005
HG Striegel, **S Laufer**, K Tollmann, S Tries
US Patent 6,936,632

136 Licofelone, a novel 5-LOX/COX-inhibitor, attenuates leukocyte rolling and adhesion on endothelium under flow 2005
H Ulbrich, O Soehnlein, X Xie, EE Eriksson, L Lindbom, W Albrecht, **S Laufer**, G Dannhardt
Biochemical pharmacology 70 (1), 30-36

135 The regulation of human MMP-13 by licofelone, an inhibitor of cyclo-oxygenases and 5-lipoxygenase, in human osteoarthritic chondrocytes is mediated by the inhibition of the p38 … 2005
C Boileau, JP Pelletier, G Tardif, H Fahmi, **S Laufer**, M Lavigne, J Martel-Pelletier
Annals of the rheumatic diseases 64 (6), 891-898

134 Mass spectrometric identification of modified urinary nucleosides used as potential biomedical markers by LC–ITMS coupling 2005
B Kammerer, A Frickenschmidt, CE Müller, **S Laufer**, CH Gleiter, H Liebich
Analytical and bioanalytical chemistry 382, 1017-1026

133 MALDI-TOF MS analysis of urinary nucleosides 2005
B Kammerer, A Frickenschmidt, CH Gleiter, **S Laufer**, H Liebich
Journal of the American Society for Mass Spectrometry 16, 940-947

132 Cytokines and growth factors in the treatment of osteoarthritis: what could be the best disease modifying drugs 2005
J Martel-Pelletier, G Tardif, **S Laufer**, JP Pelletier
Current Medicinal Chemistry-Anti-Inflammatory & Anti-Allergy Agents 4 (3 …

131 Naproxen induziert einen indirekten Cyclooxygenase-Lipoxygenase Shunt in der gastroduodenalen humanen Mucosa 2005
A Link, T Wex, M Vieth, **S Laufer**, P Malfertheiner, G Treiber

Zeitschrift für Gastroenterologie 43 (05), P024

130 PGE2 in the regulation of programmed erythrocyte death 2005
PA Lang, DS Kempe, S Myssina, V Tanneur, C Birka, **S Laufer**, F Lang, T Wieder, SM Huber
Cell Death & Differentiation 12 (5), 415-428

129 Achiral–chiral LC/LC–MS/MS coupling for determination of chiral discrimination effects in phenprocoumon metabolism 2005
B Kammerer, R Kahlich, M Ufer, **S Laufer**, CH Gleiter
Analytical biochemistry 339 (2), 297-309

128 Anti-inflammatory oxo derivatives and hydroxy derivatives of pyrrolizines, and their pharmaceutical use 2005
S Laufer, K Tollmann, HG Striegel
US Patent 6,878,738

127 Leukotriene and prostaglandin synthesis pathways in osteoarthritic synovial membranes: regulating factors for interleukin 1beta synthesis. 2005
P Marcouiller, JP Pelletier, M Guévremont, J Martel-Pelletier, P Ranger, **S Laufer**, P Reboul
The Journal of rheumatology 32 (4), 704-712

126 (3RS, 1SR)-3-Bromo-3-(1-phenylpropyl) chroman-2, 4-dione 2005
D Schollmeyer, B Kammerer, C Peifer, **S Laufer**
Acta Crystallographica Section E: Structure Reports Online 61 (4), o868-o869

125 4-Pyridyl-and 2, 4-pyrimidinyl-substituted pyrrole derivatives and their use in pharmacy 2005
HG Striegel, **S Laufer**, K Tollmann, S Tries
US Patent 6,867,211

124 Synthesis and biological testing of purine derivatives as potential ATP-competitive kinase inhibitors 2005
SA Laufer, DM Domeyer, TRF Scior, W Albrecht, DRJ Hauser
Journal of medicinal chemistry 48 (3), 710-722

123 An immunosorbent, nonradioactive p38 MAP kinase assay comparable to standard radioactive liquid-phase assays 2005
S Laufer, S Thuma, C Peifer, C Greim, Y Herweh, A Albrecht, F Dehner
Analytical biochemistry 1 (344), 135-137

122 Tetrasubstituted imidazole inhibitors of cytokine release: probing substituents in the N-1 position 2004
SA Laufer, W Zimmermann, KJ Ruff
Journal of medicinal chemistry 47 (25), 6311-6325

121 Mass spectrometric pathway monitoring of secondary metabolites: systematic analysis of culture extracts of Streptomyces species
B Kammerer, R Kahlich, **S Laufer**, SM Li, L Heide, CH Gleiter

Analytical biochemistry 335 (1), 17-29

120 Regulation of the expression of 5-lipoxygenase–activating protein/5-lipoxygenase and the synthesis of leukotriene B_4 in osteoarthritic chondrocytes: Role of … 2004
J Martel-Pelletier, F Mineau, H Fahmi, **S Laufer**, P Reboul, C Boileau, M Lavigne, JP Pelletier
Arthritis & Rheumatism 50 (12), 3925-3933

119 Regulation of the expression of FLAP/5-LOX and synthesis of LTB4 in osteoarthritic chondrocytes: Role of TGF-beta and eicosanoids 2004
J Martel-Pelletier, F Mincau, H Fahmi, **S Laufer**, P Reboul, C Boileau, M Lavigne, JP Pelletier
Arthritis and Rheumatism 50 (9), S286-S286

118 Licofelone, a novel 5-LOX/COX-inhibitor, attenuates leukocyte rolling and adhesion on endothelium under flow 2004
H Ulbrich, EE Eriksson, X Xie, O Soehnlein, L Lindbom, **S Laufer**, G Dannhardt
ANNALS OF THE RHEUMATIC DISEASES 63, 137-137

117 NSAIDs and lipo-oxygenase/cyclo-oxygenase products modulte dendritic cell function 2004
S Fiorucci, A Di Lorenzo, S Farneti, M Barbanti, **S Laufer**, E Palazzini
ANNALS OF THE RHEUMATIC DISEASES 63, 132-133

116 The gastrointestinal tolerability of the LOX/COX inhibitor, licofelone, is similar to placebo and superior to naproxen therapy in healthy volunteers: results from a randomized … 2004
P Bias, A Buchner, B Klesser, **S Laufer**
Official journal of the American College of Gastroenterology| ACG 99 (4), 611-618

115 2-Tiosubstituované imidazolové deriváty a ich použitie vo farmácii 2004
S Laufer, D Kotschenreuther, P Merckle, K Tollmann

114 The inhibition of subchondral bone resorption in the early phase of experimental dog osteoarthritis by licofelone is associated with a reduction in the synthesis of MMP-13 and … 2004
JP Pelletier, C Boileau, J Brunet, M Boily, D Lajeunesse, P Reboul, **S Laufer**, J Martel-Pelletier
Bone 34 (3), 527-538

113 Determination of (*R*)- and (*S*)-phenprocoumon in human plasma by enantioselective liquid chromatography/electrospray ionisation tandem mass spectrometry 2004
B Kammerer, R Kahlich, M Ufer, **S Laufer**, CH Gleiter
Rapid communications in mass spectrometry 18 (4), 458-464

112 Composto, composição farmacêutica, uso de pelo menos um composto, e, método para tratar distúrbios associados com um sistema imune perturbado 2004
S Laufer, D Kotschenreuther, P Merckle, K Tollmann, HG Striegel

111 Osteoarthritis therapy—are there still unmet needs? 2004
S Laufer
Rheumatology 43 (suppl_1), i9-i15

110 Treatment with licofelone prevents abnormal subchondral bone cell metabolism in experimental dog osteoarthritis 2004
D Lajeunesse, J Martel-Pelletier, JC Fernandes, **S Laufer,** JP Pelletier
Annals of the rheumatic diseases 63 (1), 78-83

109 Combined approach for analysis of biological activity of compounds 2004
MA Grishina, VA Potemkin, KM Mikuchina, GV Pozhilenkova, **S Laufer**
Biomeditsinskaya khimiya 50 (app1), 68-76

108 The regulation of human metalloprotease-13 by licofelone, an inhibitor of cyclooxygenases and 5-lipoxygenase, in human osteoarthritic chondrocytes is mediated by the inhibition … 2004
C Boileau, JP Pelletier, F Mineau, G Tardif, H Fahmi, **S Laufer**, M Lavigne, J Martel-Pelletier
OSTEOARTHRITIS AND CARTILAGE 12, S100-S100

107 Genetic algorithm for molecular 3D drug design 2004
VA Potemkin, MA Grishina, GV Pozhilenkova, KM Mikuchina, **S Laufer**
Biomeditsinskaya khimiya 50 (app1), 42-48

106 COX-3—a virtual pain target in humans? 2003
JM Schwab, T Beiter, JU Linder, **S Laufer**, JE Schulz, R Meyermann, HJ Schluesener
The FASEB journal 17 (15), 2174-2175

105 Inhibition of human MMP-13 expression by licofelone, a dual inhibitor of cyclooxygenase/5-lipoxygenase in human osteoarthritic (OA) chondrocytes. 2003
C Boileau, JP Pelletier, **S Laufer**, P Ranger, J Martel-Pelletier
ARTHRITIS AND RHEUMATISM 48 (9), S283-S283

104 Role of eicosanoids in structural degradation in osteoarthritis 2003
S Laufer
Current opinion in rheumatology 15 (5), 623-627

103 Novel substituted pyridinyl imidazoles as potent anticytokine agents with low activity against hepatic cytochrome P450 enzymes 2003
SA Laufer, GK Wagner, DA Kotschenreuther, W Albrecht
Journal of medicinal chemistry 46 (15), 3230-3244

102 Study of cross talking between leukotriene and prostaglandin synthetic pathways in human OA synovial membranes: Mechanisms of regulation 2003

P Reboul, P Marcouiller, **S Laufer**, J Martel-Pelletier, JP Pelletier
ANNALS OF THE RHEUMATIC DISEASES 62, 114-115

101 Selective COX-2 inhibitors, but not licofelone, a LOX/COX inhibitor, inhibit anti-adhesive activity of aspirin 2013
S Fiorucci, A Mencarelli, E Distrutti, **S Laufer**, M Barbanti, E Palazzini, A Morelli, JL Wallace
ANNALS OF THE RHEUMATIC DISEASES 62, 116-116

100 Inhibition of human MMP-13 expression by licofelone, a dual inhibitor of cyclooxygenases/5-lipoxygenase in human osteoarthritic chondrocytes 2003
C Boileau, JP Pelletier, **S Laufer**, P Ranger, J Martel-Pelletier
ANNALS OF THE RHEUMATIC DISEASES 62, 262-263

99 International Conference on Inflammopharmacology–VIII Side-Effects of Anti-Inflammatory Drugs Symposium 2003
S Laufer
Expert Opinion on Investigational Drugs 12 (7), 1239-1241

98 Identification of Regioisomers in a Series of N-Substituted Pyridin-4-yl Imidazole Derivatives by Regiospecific Synthesis, GC/MS, and ^{1}H NMR 2003
GK Wagner, D Kotschenreuther, W Zimmermann, **SA Laufer**
The Journal of organic chemistry 68 (11), 4527-4530

97 COX-3: just another COX or the solitary elusive target of paracetamol? 2003
JM Schwab, HJ Schluesener, **S Laufer**
The Lancet 361 (9362), 981-982

96 Influence of willow bark extract on cyclooxygenase activity and on tumor necrosis factor alpha or interleukin 1 beta release in vitro and ex vivo. 2003
I Wagner, C Greim, **S Laufer**, L Heide, CH Gleiter
Clinical pharmacology and therapeutics 73 (3), 272-274

95 NO-Donors. Part 7. Synthesis and Cyclooxygenase Inhibitory Properties of N-and S-Nitrooxypivaloyl-cysteine Derivatives of Naproxen—A Novel Type of NO-NSAID. 2003
RE Kartasasmita, **S Laufer**, J Lehmann
ChemInform 34 (4), no-no

94 Inflammation and rheumatic diseases. The molecular basis of novel therapies 2003
F Calanni, **S Laufer**
Biochemistry and mediators of inflammation. Georg Thieme Verlag, Stuttgart

93 Inflammation and Rheumatic Diseases: The molecular basis of novel therapies 2003
S Laufer, S Gay, K Brune
Georg Thieme Verlag

92 Biochemistry and mediators of inflammation 2003

F Calanni, **S Laufer**
Inflammation and Rheumatic Diseases. The Molecular Basis of Novel Therapies. Georg Thieme Verlag

91 LETTERS TO THE EDITOR-Influence of willow bark extract on cyclooxygenase activity and on tumor necrosis factor a or interleukin 1b release in vitro and ex vivo 2003
I Wagner, C Greim, **S Laufer**, L Heide, CH Gleiter
Clinical Pharmacology and Therapeutics 73 (3), 272-273

90 Antitubercular Isoniazid and Drug Resistance of *Mycobacterium tuberculosis* — A Review 2002
T Scior, I Meneses Morales, SJ Garcés Eisele, D Domeyer, **S Laufer**
Archiv der Pharmazie: An International Journal Pharmaceutical and Medicinal Chemistry 335 (11-12), 511-525

89 An in-vitro screening assay for the detection of inhibitors of proinflammatory cytokine synthesis: a useful tool for the development of new antiarthritic and disease modifying … 2002
S Laufer, C Greim, T Bertsche
Osteoarthritis and cartilage 10 (12), 961-967

88 NO-Donors (VII [1]): Synthesis and Cyclooxygenase Inhibitory Properties of *N*-and *S*-Nitrooxypivaloyl-cysteine Derivatives of Naproxen — A Novel Type of NO … 2002
RE Kartasasmita, **S Laufer**, J Lehmann
Archiv der Pharmazie: An International Journal Pharmaceutical and Medicinal Chemistry 335 (8) 363-366

87 Imidazole inhibitors of cytokine release: probing substituents in the 2 position 2002
SA Laufer, HG Striegel, GK Wagner
Journal of medicinal chemistry 45 (21), 4695-4705

86 Discovery and development of LICOFELONE (ML3000) 2002
S Laufer, S Tries, HG Striegel, P Bias, A Buchner
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY 58 (7), S100-S100

85 2-Thio-substituierte Imidazolderivate und ihre Verwendung in der Pharmazie 2002
S Laufer, D Kotschenreuther, P Merckle, K Tollmann, HG Striegel

84 2-arylalkylthio-imidazoles, 2-arylalkenyl-thio-imidazoles and 2-arylalkinyl-thio-imidazoles as anti-inflammatory substances and substances inhibiting the release of cytokine 2002
S Laufer, HG Striegel, K Neher
US Patent 6,432,988

83 Process for preparing 6-(4-chlorophenyl)-2, 2-dimethyl-7-phenyl-2, 3-dihydro-1H-pyrrolizin-5-yl-acetic acid 2002

T Kammermeier, **S Laufer**, P Merckle, HG Striegel
US Patent 6,417,371

82 Ones, Thiones, and *N*-Oxides: An Exercise in Imidazole Chemistry 2002
S Laufer, G Wagner, D Kotschenreuther
Angewandte Chemie International Edition 41 (13), 2290-2293

81 One, Thione und N-Oxide: ein allgemeiner Zugang zu Imidazolderivaten 2002
S Laufer, G Wagner, D Kotschenreuther
Angewandte Chemie 114 (13), 2408-2411

80 Licofelone (ML-3000), a dual inhibitor of 5-lipoxygenase and cyclooxygenase, reduces the level of cartilage chondrocyte death in vivo in experimental dog osteoarthritis … 2002
C Boileau, J Martel-Pelletier, JY Jouzeau, P Netter, F Moldovan, **S Laufer,** S Tries, JP Pelletier
The Journal of Rheumatology 29 (7), 1446-1453

79 Study of the role of leukotriene B_4 in abnormal function of human subchondral osteoarthritis osteoblasts: Effects of cyclooxygenase and/or 5-lipoxygenase inhibition 2002
Y Paredes, F Massicotte, JP Pelletier, J Martel-Pelletier, **S Laufer**, D Lajeunesse
Arthritis & Rheumatism: Official Journal of the American College of Rheumatology 46 (7) 1804-1812

78 From imidazoles to pyrimidines: new inhibitors of cytokine release 2002
SA Laufer, GK Wagner
Journal of medicinal chemistry 45 (13), 2733-2740

77 Studies on the anti-inflammatory activity of phytopharmaceuticals prepared from Arnica flowers 2002
CA Klaas, G Wagner, **S Laufer**, S Sosa, R Della Loggia, U Bomme, HL Pahl, I Merfort
Planta medica 68 (05), 385-391

76 Synthesis of interleukin 1beta, tumor necrosis factor-alpha, and interstitial collagenase (MMP-1) is eicosanoid dependent in human osteoarthritis synovial membrane explants … 2002
W He, JP Pelletier, J Martel-Pelletier, **S Laufer**, JA Di Battista
The Journal of Rheumatology 29 (3), 546-553

75 Antithrombotic and platelet function inhibiting effects of ML3000, a new antiinflammatory drug with Cox/5-LOX inhibitory activity 2002
S Tries, **S Laufer**, P Radziwon, HK Breddin
Inflammation Research 51, 129-134

74 The mechanism of action of the new antiinflammatory compound ML3000: inhibition of 5-LOX and COX-1/2 2002
S Tries, W Neupert, **S Laufer**
Inflammation Research 51, 135-143

73 Neue NSAR: Was bietet die Zukunft? 2002
S Laufer
Pharmazie in unserer Zeit 31 (2), 164-169

72 Synthesis of IL-1b, TNF-a, and Interstitial Collagenase (MMP-1) Is Eicosanoid Dependent in Human OA Synovial Membrane Explants: Interactions with Antiinflammatory Cytokines 2002
W He, JP Pelletier, J Martel-Pelletier, **S Laufer**, JA DiBattista
Journal of Rheumatology 29 (3), 546-553

71 Biochemie und Mediatoren der Entzündung 2002
S Laufer
Rheumatische Erkrankungen und Entzündung: Von den molekularen Grundlagen zur medikamentösen Therapie, Georg Thieme Verlag

70 Rheumatische Erkrankungen und Entzündung: von den molekularen Grundlagen zur medikamentösen Therapie; 26 Tabellen 2002
S Laufer, S Gay, K Brune
Georg Thieme Verlag

69 Osteoarthritis and Cartilage-Study of the Role of Leukotriene B4 in Abnormal Function of Human Subchondral Osteoarthritis Osteoblasts: Effects of Cyclooxygenase and/or 5 … 2002
Y Paredes, F Massicotte, JP Pelletier, J Martel-Pelletier, **S Laufer**, D Lajeunesse
Arthritis and Rheumatism 46 (7), 1804-1812

68 Neue und zukünftige Therapieansätze 2002
S Laufer
Laufer, S., Gay, G., Brune K.: Rheumatische Erkrankungen und Entzündung. Georg Thieme Verlag

67 In vivo dual inhibition of cyclooxygenase and lipoxygenase by ML-3000 reduces the progression of experimental osteoarthritis: Suppression of collagenase 1 and interleukin-1β … 2001
DV Jovanovic, JC Fernandes, J Martel-Pelletier, FC Jolicoeur, P Reboul, **S Laufer**, S Tries, JP Pelletier
Arthritis & Rheumatism 44 (10), 2320-2330

66 The in vivo dual inhibition of cyclooxygenase and lipoxygenase by ML-3000 reduces the progression of experimental osteoarthritis: Suppression of collagenase-1 and interleukin-1 … 2001
JP Pelletier, JC Fernandes, FC Jolicoeur, P Reboul, S Laufer, S Tries, J Martel-Pelletier
ARTHRITIS AND RHEUMATISM 44 (9), S307-S307

65 Dual inhibition of 5-lipoxygenase and cyclooxygenases 1 and 2 by ML3000 reduces joint destruction in adjuvant arthritis. 2001
RE Gay, M Neidhart, F Pataky, S Tries, **S Laufer**, S Gay
The Journal of Rheumatology 28 (9), 2060-2065

64 Role of leukotriene B-4 in abnormal function of osteoarthritic osteoblasts. 2001
D Lajeunesse, Y Paredes, F Massicotte, J Martel-Pelletier, **S Laufer**, JP Pelletier
ARTHRITIS AND RHEUMATISM 44 (9), S308-S308

63 Discovery and development of ML3000 2001
S Laufer
Inflammopharmacology 9, 101-112

62 The pharmacological profile of ML3000: A new pyrrolizine derivative inhibiting the enzymes cyclo-oxygenase and 5-lipoxygenase 2001
S Tries, **S Laufer**
Inflammopharmacology 9, 113-124

61 Anti-inflammatory drugs: new multitarget compounds to face an old problem. The dual inhibition concept 2001
F Celotti, **S Laufer**
Pharmacological Research 43 (5), 429-436

60 Synthesis and Cyclooxygenase Inhibitory Properties of Novel (+) 2-(6-Methoxy-2-naphthyl) propanoic Acid (Naproxene) Derivatives 2001
AH Abadi, **S Laufer**, J Lehmann
Archiv der Pharmazie 334 (3), 104-106

59 Antiinflammatorische oxo-und hydroxyderivate von pyrrolizinen und deren anwendung in der pharmazie 2001
S Laufer, K Neher, HG Striegel

58 Effects of natural products containing acylresorcinol partial structures on cyclooxygenases and 5-lipoxygenase 2001
F Bracher, J Krauss, **S Laufer**
Pharmazie 56 (5)

57 Copyright WILEY-VCH Verlag GmbH, D-69451 Weinheim, 2001. Supporting Information for Angew. Chem. Int. Ed. Z18173 2001
S Laufer, G Wagner, D Kotschenreuther

56 Osteoarthritis and Cartilage-In Vivo Dual Inhibition of Cyclooxygenase and Lipoxygenase by ML-3000 Reduces the Progression of Experimental Osteoarthritis: Suppression of … 2001
DV Jovanovic, JC Fernandes, J Martel-Pelletier, FC Jolicoeur, P Reboul, **S Laufer**, S Tries, JP Pelletier
Arthritis and Rheumatism 44 (10), 2320-2330

55 Structural approaches to explain the selectivity of COX-2 inhibitors: is there a common pharmacophore? 2000
G Dannhardt, **S Laufer**
Current Medicinal Chemistry 7 (11), 1101-1112

54	A NOVEL AND VERSATILE SYNTHETIC APPROACH TOWARDS NI-SUBSTITUTED IMIDAZOLE DERIVATIVES D Kotschenreuther, **S Laufer** ARCHIV DER PHARMAZIE 333, 43-43	2000
53	In-vitro screening assay to evaluate cytokine release inhibitors C Donat, **S Laufer** ARCHIV DER PHARMAZIE 333, 15-15	2000
52	TOWARDS NEW INHIBITORS OF CYTOKINE RELEASE G Wagner, **S Laufer** ARCHIV DER PHARMAZIE 333, 97-97	2000
51	A!-anellated pyrrole derivatives and their use in pharmacology **S Laufer**, HG Striegel, G Dannhardt US Patent 5,958,943	1999
50	a!-Annelated pyrrole derivatives and pharmaceutical use thereof **S Laufer**, HG Striegel, G Dannhardt US Patent 5,942,535	1999
49	A!-annellated pyrrole derivatives and their use in pharmacology **S Laufer**, HG Striegel, G Dannhardt US Patent 5,939,415	1999
48	Development of an in-vitro test system for the evaluation of cyclooxygenase-2 inhibitors **S Laufer**, P Zechmeister, T Klein Inflammation research 48, 133-138	1999
47	Anti-inflammatory activity of myricetin-3-O-β-D-glucuronide and related compounds A Hiermann, HW Schramm, **S Laufer** Inflammation research 47, 421-427	1998
46	Uricosurisch wirksame Metabolite des Benzbromarons **S Laufer**, J Manner, S Tries, V Luckow, P Arnold SCIENTIA PHARMACEUTICA 66, S76-S76	1998
45	The effects of ML 3000 on antigen-induced responses in sheep WM Abraham, **S Laufer**, S Tries Pulmonary pharmacology & therapeutics 10 (3), 167-173	1997
44	Bioequivalence evaluation of two flutamide preparations in healthy female subjects. K Doser, R Guserle, R Kramer, **S Laufer**, K Lichtenberger Arzneimittel-forschung 47 (2), 213-217	1997
43	Synthesis and evaluation of a novel series of pyrrolizine derivatives as dual cyclooxygenase-1 and 5-lipoxygenase inhibitors	1997

S Laufer, HG Striegel, K Neher, P Zechmeister, C Donat, K Stolingwa, S Baur, S Tries, T Kammermeier, G Dannhardt, W Kiefer
Archiv der Pharmazie 330 (9-10), 307-312

42 Synthesis and biological identification of the acyl glucuronide of the antiinflammatory drug ML-3000 1997
A Kirschning, M Ries, S Domann, W Martin, W Albrecht, P Arnold, **S Laufer**
Bioorganic & Medicinal Chemistry Letters 7 (7), 903-906

41 Efficient Synthesis of New 2-Cycloalk (en) ylpropanoic Acid Derivatives—Medium and Large Rings as Bioisosteres of Alkylphenyl Moieties? 1996
B Greve, P Imming, **S Laufer**
Angewandte Chemie International Edition in English 35 (11), 1221-1223

40 Effiziente Synthese neuer 2-Cycloalk (en) yl-propansäure-Derivate–mittlere und große Ringe als Bioisostere von Alkylphenylresten? 1996
B Greve, P Imming, **S Laufer**
Angewandte Chemie 108 (11), 1312-1314

39 Regioisomeric 5 (3)-aminomethyl-3 (5)-phenylisoxazoles: synthesis, spectroscopic discrimination, and muscarinic activity. 1995
G Dannhardt, G Lambrecht, **S Laufer**, E Mutschler, J Schweiger
Archiv der Pharmazie 328 (5), 437-443

38 Studies on the in vitro and in vivo genotoxicity of [2, 2-dimethyl-6-(4-chlorophenyl)-7-phenyl-2, 3-dihydro-1H-pyrrolizine-5-yl]-acetic acid 1995
A Heidemann, S Tries, **S Laufer**, J Augustin
Arzneimittel-Forschung 45 (4), 486-490

37 Distribution and excretion of [14C]-labelled [2, 2-dimethyl-6-(4-chlorophenyl)-7-phenyl-2, 3-dihydro-1H-pyrrolizine-5-yl]-[2'-14C]-acetic acid in rats. 1995
HP Deigner, CE Freyberg, **S Laufer**
Arzneimittel-forschung 45 (3), 272-276

36 General pharmacology of [2, 2-dimethyl-6-(4-chlorophenyl)-7-phenyl-2, 3-dihydro-1H-pyrrolizine-5-yl]-acetic acid in experimental animals. 1995
DR Algate, J Augustin, PR Atterson, DJ Beard, CM Jobling, **S Laufer**, PL Munt, S Tries
Arzneimittel-forschung 45 (2), 159-165

35 Acute and chronic anti-inflammatory properties of [2, 2-dimethyl-6-(4-chlorophenyl)-7-phenyl-2, 3-dihydro-1H-pyrrolizine-5-yl]-acetic acid. 1995
S Laufer, S Tries, J Augustin, R Elsässer, W Albrecht, R Guserle, DR Algate, PR Atterson, PL Munt
Arzneimittel-forschung 45 (1), 27-32

34 In-vitro test system for the evaluation of dual cyclooxygenase and 5-lipoxygenase inhibitors 1995
S Laufer, K Neher, B Bayer, J Homann, E Reutter, S Tries

Pharmaceutical and Pharmacological Letters 5 (4), 166-169

33 Regioisomeric 3-, 4-and 5-aminomethyl isoxazoles: synthesis and muscarinic activity 1995
G Dannhardt, W Kiefer, G Lambrecht, **S Laufer**, E Mutschler, J Schweiger, HG Striegel
European journal of medicinal chemistry 30 (11), 839-850

32 ML 3000 reduces gastric prostaglandin synthesis without causing mucosal injury 1994
JL Wallace, L Carter, W McKnight, S Tries, **S Laufer**
European journal of pharmacology 271 (2-3), 525-531

31 Gastrointestinal tolerance of [2, 2-dimethyl-6-(4-chlorophenyl-7-phenyl-2, 3-dihydro-1H-pyrrolizine-5-yl]-acetic acid in the rat. 1994
S Laufer, S Tries, J Augustin, R Elsässer, DR Algate, PR Atterson, PL Munt
Arzneimittel-forschung 44 (12), 1329-1333

30 P59 Diarylpyrrolizines; dual inhibitors of CO and 5-LO 1994
S Laufer, S Tries, J Augustin
European Journal of Pharmaceutical Sciences 2 (1-2), 133

29 (6, 7-Diaryldihydropyrrolizin-5-yl) acetic acids, a novel class of potent dual inhibitors of both cyclooxygenase and 5-lipoxygenase 1994
SA Laufer, J Augustin, G Dannhardt, W Kiefer
Journal of medicinal chemistry 37 (12), 1894-1897

28 Pharmacological profile of a new pyrrolizine derivative inhibiting the enzymes cyclo-oxygenase and 5-lipoxygenase. 1994
S Laufer, S Tries, J Augustin, G Dannhardt
Arzneimittel-forschung 44 (5), 629-636

27 Duale Hemmstoffe der Cyclooxygenase und 5-Lipoxygenase; ein neuer Ansatz zur Entwicklung nebenwirkungsarmer NSAR 1994
S Laufer, S Tries, J Augustin, G Dannhardt
SCIENTIA PHARMACEUTICA 62, 167-167

26 Hypertensive effects and structure-activity relationships of 5-omega-aminoalkyl isoxazoles. 1993
G Dannhardt, P Dominiak, **S Laufer**
Arzneimittel-forschung 43 (4), 441-444

25 5-(β-Aminoethyl) aminoisoxazoles with Hypertensive Activity: Synthesis and Screening of Isoxazolopyrazines and Isoxazolodiazepines. 1991
G DANNHARDT, P DOMINIAK, **S LAUFER**
ChemInform 22 (28), no-no

24 5-((β-Aminoethyl) amino) isoxazoles with Hypertensive Activity: Synthesis and Screening of Derivatives with Partially Rigid C-5 Side Chains and Heterocycles at the ω-Position … 1991

G Dannhardt, P DOMINIAK, **S LAUFER**
ChemInform 22 (2), no-no

23 Hypertensiv wirksame 5-(β-Aminoethyl) aminoisoxazole: Synthese und Prüfung von Isoxazolopyrazinen und Isoxazolodiazepinen 1991
G Dannhardt, P Dominiak, **S Laufer**
Archiv der Pharmazie 324 (3), 141-148

22 Hypertensive acting 5-(beta-aminoethyl) aminoisoxazoles: synthesis and screening of derivatives with with partially rigid C-5 side chains and omega-position heterocyclics 1990
G Dannhardt, P Dominiak, **S Laufer**
Archiv der Pharmazie 323 (9), 571-578

21 Hypertensive action of 5-(omega-aminoalkyl) aminoisoxazole: synthesis and testing of compounds with a sulfamide or carboxyl group on the end of side chain 1990
G Dannhardt, P Dominiak, **S Laufer**
Archiv der Pharmazie 323 (8), 517-519

20 5-(OMEGA-AMINOALKYL) AMINOISOXAZOLES WITH HYPERTENSIVE ACTIVITY-SYNTHESIS AND SCREENING OF COMPOUNDS WITH A SULFAMIDE OR CARBOXYL FUNCTION AT THE END OF THE SIDE-CHAIN 1990
G DANNHARDT, P DOMINIAK, **S LAUFER**
ARCHIV DER PHARMAZIE 323 (8), 517-519

19 Ring Transformations of 2-Phenacylidenimidazolidines: Synthesis of 5-(β-Aminoethyl) anilinopyrazoles and 2-Acyl-3-(β-aminoethyl) aminothiophenes. 1990
G Dannhardt, **S Laufer**
ChemInform 21 (7), no-no

18 Hypertensiv wirksame 5-(ω-Aminoalkyl) aminoisoxazole: Synthese und Prüfung von Verbindungen mit einer Sulfamid-oder Carboxyl-Gruppe am Ende der Seitenkette 1990
G Dannhardt, P Dominiak, **S Laufer**
Archiv der Pharmazie 323 (8), 517-519

17 Hypertensiv wirksame 5-(β-Aminoethyl) aminoisoxazole: Synthese und Prüfung von Derivaten mit teilrigidisierter C-5-Seitenkette bzw. ω-ständigem Heterocyclus 1990
G Dannhardt, P Dominiak, **S Laufer**
Archiv der Pharmazie 323 (9), 571-578

16 A New Synthesis of 3, 4-Diaryl-5-oxo-4, 5-dihydroisoxazoles and Their Transformation to 5-(N-(ω-Aminoalkyl) amino) isoxazoles and 5-(2-Aminoethylthio) isoxazoles. 1989
G Dannhardt, **S Laufer**, I Obergrusberger
ChemInform 20 (37), no-no

15 Ring Transformation of 2-Phenacylidenimidazolidines into 5-(2-Aminoethyl)-3-aryl-5-phenylaminoisoxazoles. 1989
G Dannhardt, **S Laufer**
ChemInform 20 (23), no-no

14 5-(2-Aminoethyl)-3-aryl-5-phenylaminoisoxazole durch Ringtransformation von 2-Phenacylidenimidazolidinen 1989
G Dannhardt, **S Laufer**
Synthesis 1989 (01), 12-15

13 Eine neue Synthese für 3, 4-Diaryl-5-oxo-4, 5-dihydroisoxazole und ihre Überführung in 5-[N-(ω-Aminoalkyl) amino) isoxazole und 5-(2-Aminoethylthio) isoxazole 1989
G Dannhardt, **S Laufer**, I Obergrusberger
Synthesis 1989 (04), 275-280

12 HPLC determination of etofenamate and flufenamic acid in biological material. 1988
G Dannhardt, **S Laufer**, M Lehr
Clinical chemistry 34 (12), 2580-2581

11 PREPARATION AND CARDIOVASCULAR ACTIVITY OF 5-OMEGA-AMINO-ALKYL (-HETEROALKYL) ISOXAZOLENE 1988
G DANNHARDT, P DOMINIAK, **S LAUFER**
ARCHIV DER PHARMAZIE 321 (9), 576-576

10 Enaminodiesters and Monoesters with a Semicyclic C⎦ C-Bond of the Pyrrolidine and Imidazolidine Series 1988
G Dannhardt, **S Laufer**, K Ziereis
Archiv der Pharmazie 321 (7), 429-430

9 Unselective COX Inhibitors 1988
SA Laufer

8 TÍTULO DO TRABALHO: TRITERPENÓIDE ISOLADO DAS PARTES AÉREAS DE Senecio selloi Spreng. DC.: AVALIAÇÃO DAS ATIVIDADES ANTIINFLAMATÓRIA E ANESTÉSICA GERAL.
GNS DA SILVA, MA DA CUNHA, B BALDISSEROTTO, **S LAUFER**, CA MALLMANN, BM HEINZMANN

7 Identification of Urinary Nucleosides
D Bullinger, A Frickenschmidt, M Pelzing, T Zey, G Zurek, **S Laufer**, B Kammerer

6 Structure and Metabolic Function of COX-1
SA Laufer

5 PHYTOCHEMICAL AND BIOLOGICAL STUDIES OF THE BARK FROM PARAPIPTADENIA RIGIDA
CA Schmidt, M Fronza, M Goettert, R Murillo, V Brecht, B Heinzmann, **S Laufer**, I Merfort

4 COX-3Oa virtual pain target in humans?
J SCHWAB, T BEITER, JU LINDER, **S LAUFER**, JE SCHULZ, R MEYERMANN, HJ SCHLUESENER

3 p38 MAP-KINASE INHIBITORS AND THEIR CYP-450 INTERFERENCE: AN OPTIMIZATION
K Ruff, D Kotschenreuther, **S Laufer**

2 Small Molecule Inhibitors OF Cytokine Release Bioisosteric Replacement
MD Fritz, **S Laufer**

1 Covalent Inhibitors re-invented
P Koch, F Muth, M Günther, M Juchum, M Forster, D Rauh, S Knapp, **SA Laufer**
Artikel 1–633